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T cells have a central role in the immune system by participating in and 
coordinating the overall immune response, including the antigen recognition, T cell 
activation and effector functions. T cells communicate with other cells by the 
interaction of various surface molecules with their ligands, and these surface 
molecules serve two important functions of co-stimulation and adhesion in T cell 
activation. Many efforts have been made to develop inhibitors of these adhesion or 
co-stimulatory molecules into immune suppressive drug candidates for auto-immune 
diseases and transplantation rejection.  
CD2 is an important T cell adhesion molecule with dual functions of adhesion as 
well as signal transduction by binding to its ligands, CD58 (in human) and CD48 (in 
rats). CD2-CD58 interaction has important role in modulating antigen recognition and 
T cell activation. Antibodies to CD2 and CD58 have been shown to inhibit T cell 
activation. CD2-CD58 interaction is also found to be involved in the pathology of 
some diseases. Moreover, the Ig fusion protein of LFA-3 (CD58) has been approved 
to treat psoriasis by interrupting CD2-CD58 interaction. Therefore, T cell adhesion 
molecule CD2 serves as an attractive target for developing immunosuppressive 
agents.  
The hypothesis of this project is that the small peptides derived from CD2 ligand 
binding epitopes can modulate CD2-CD58 interaction by mimicking the native β-turn 
structure. 12-amino acid cyclic peptides (cER and cVL from rat CD2; cAQ and cIL 
 x 
from human CD2) were initially designed from critical β-turns connecting or linking 
important CD2 interface β-strands (CC’, C’C’’ and FG loop). The parent peptides 
were then subjected to truncation and alanine scanning for optimization. Finally, the 
biological activity and secondary structure of the peptides were investigated to 
elucidate the Structure-Activity Relationship (SAR). 
A specific and sensitive OVCAR-Jurkat heterotypic cell adhesion assay was 
developed and optimized to access CD2-CD58 interaction. Investigation of the 
adhesion mechanism suggested that OVCAR-Jurkat heterotypic assay mainly targeted 
CD2 medicated adhesion pathway instead of LFA-1 mediated adhesion pathway.  
The inhibitory effects of peptides on CD2-CD58 interaction were investigated 
with the new heterotypic cell adhesion assay as well as traditional E-rosetting 
inhibition assay, both of which presumably targeted CD2-CD58 interaction. Parent 
peptides showed high inhibitory activity in the biological assays, and truncation 
studies indicated the existence of minimum inhibitory sequence (MIS) in parent 
peptides. Alanine scanning suggested specific residues, such as residue in β-turn (Ser4 
in cEL) or residue flanking β-turn (Val 2 in cVL), were critical for the inhibitory 
activity. All the test peptides showed no cytotoxticity on Jurkat or OVCAR cells, nor 
inhibitory activity on LFA-1/ICAM-1 cell adhesion. 
CD and NMR experiments were carried out to study the secondary structure of 
peptides, and NMR constrained molecular modeling (NMR-MD) was used to 
determine the 3 dimensional structure of peptides. Structural studies indicated that 
 xi 
MIS peptides (cQT, cIN and cVR) adopted stable β-turn structure in solution, while 
alanine mutations (R2A, S4A) resulted in residue shift or loss of stable β-turn 
structure.  
The structure-activity relationship supported our hypothesis that small cyclic 
peptides derived from CD2 ligand binding epitopes could mimic native β-turn 
structure in the native protein thus modulate CD2-CD58 interaction. Our studies were 
useful for structure-based design of potential peptides or peptidomimetics modulating 
CD2-CD58 interaction for auto-immune diseases or transplantation rejection. 
 xii 
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1.1 Overview of immune system and immune response 
1.1.1 Immune system and immune response  
The immune system is a complicated network of organs, cells and cell molecules 
designed to protect the host against foreign pathogens (bacteria, viruses, fungi and 
other invading antigens) as well as against tumor development. The immune system is 
typically divided into two categories--innate and adaptive immunity. The innate 
immunity is nonspecific and continually ready to respond to the invasion, which 
includes physical barriers (skin, gastrointestinal (GI) tract), molecules in bodily 
secretions (such as tears and saliva) and cellular components (such as granulocytes 
and macrophages). On the other hand, acquired or adaptive immunity refers to antigen 
(Ag)-specific immune response in which different kinds of immune system cells 
interact with one another to mount a coordinated immune response and at the same 
time, a long-lasting memory of specific pathogen is achieved [1]. 
The adaptive immunity is composed of B-lymphocyte mediated humoral 
immunity and T-lymphocyte mediated celluar immunity. Humoral immunity is 
particularly effective against extracellular pathogens while T cell-mediated immunity 
is effective against intracellular pathogens, both of which contribute to the specific 
adaptive immune system. In response to infection, activated B-cells develop into 
plasma cells that secrete soluble recognition molecules (antibody, Ab) or long-lived 
memory cells that respond very quickly upon subsequent encounter with the same Ag 
(secondary response) [1]. The specific Abs diffuse through tissues to bind 
  





extracellular pathogens, which in turn activate different effector mechanisms 
(neutralization, opsonization and complement activation) to eliminate the pathogens 
[1, 2]. On the contrary, T cell mediated immunity involves the production of cytotoxic 
T-lymphocytes (CTLs), activated macrophages and natural killing (NK) cells, as well 
as the production of cytokines. The CTLs are able to lyse virus-infected or tumor cells 
displaying foreign Ag on their surface. The activated macrophages and NK cells can 
destroy intracellular pathogens residing in major intracellular compartments [1, 3]. 
1.1.2 Cells of the immune system 
Cells involved in our immune system are collectively referred to as white blood 
cells or leukocytes, which comprise lymphocytes (T cells and B cells), NK cells and a 
variety of phagocytes (including granulocytes, monocytes/macrophages or dendritic 
cells). These cells coordinate to achieve effective immune responses against foreign 
invaders. For example, granulocytes (especially neutrophils) and macrophages can 
engulf and digest invading organisms thus important for innate immunity. Dendritic 
cells (DC), macrophages and as well as B cells function as antigen-presenting cells 
(APC) and present foreign antigens to other cells of the immune system such as T 
cells and B cells, which can recognize and remember specific antigens thus are 
critical for acquired immunity [4]. 
Lymphocytes have evolved to specifically recognize the wide range of pathogens 
an individual will encounter. Each lymphocyte is specific for a particular Ag because 
each binds to a particular molecular structure by the receptor on the surface. The 
  





Ag-recognition molecules of B cells are the immunoglobulins (Ig) that bind to soluble 
antigens. The membrane-bound Ig serves as B cell receptor (BCR) and the secreted Ig 
of the same antigen specificity is known as antibody (Ab). On the other hand, T cells 
recognize foreign antigens displayed on the surfaces of the body’s own cells. The 
foreign antigen is processed into a small peptide fragment bound to a major 
histocompatibility complex (MHC) molecule of a target cell (MHC class I) or APC 
(MHC class II), and the formed peptide-MHC complex (pMHC) is displayed on the 
surface of host cells and then recognized by T cell receptor (TCR) on T cell surface 
[1].  
T cells and B cells develop in bone marrow from a common precursor but mature 
in thymus and bone marrow respectively. Once lymphocytes complete their 
development in the central lymphoid tissues, they enter the bloodstream and are 
carried by the circulation. Upon reaching a peripheral lymphocyte tissue, they leave 
the blood to migrate through the lymphocyte tissue, returning to the bloodstream to 
circulate between blood and peripheral lymphocyte tissues until they encounter 
specific antigens. Once activated by Ag, naïve T cells secret a soluble hormone-like 
growth factor, interleukin 2 (IL-2) and express IL-2 receptor on the surface. In the 
presence of IL-2, naïve T cells proliferate into clonal populations and develop effector 
capabilities through differentiation. There are two major subsets of effector T cells: 
Helper T cell (Th1 and Th2) that is CD4 positive (CD4+) and cytotoxic T cell (Tc) or 
CTL that is CD8 positive (CD8+) [1]. On the other hand, the activation B cells and 
their differentiation into effector cells (plasma cells) are triggered by Ag and usually 
  





require lymphokines released by stimulated helper T cells [1, 2]. 
T cell–B cell collaboration is necessary for an effective immunity, in which T 
cells play a central role in governing both humoral and cellular immunity (Table 1-1). 
In the humoral immunity, extracellular antigens bound to class II MHC molecules 
presented by APCs can be recognized by CD4+ Th cells and in turn activate 
Ag-specific B cells to make antibody. While in the cellular immunity, intracellular 
antigens bound to class I MHC molecules (on target cells) or class II MHC molecules 
(on macrophages) could be recognized by CD8+ CTL or CD4+ Th1 cells respectively. 
Effector CTL cells will destroy the infected target cells directly and Th1 cells will 
activate infected macrophages to clear the antigens [1, 5, 6]. 
Table 1-1 The role of effector T cells in cellular and humoral immune responses [1]. 
 Cellular immunity Humoral immunity 
Typical pathogens Virus Bacteria Bacteria toxin 
Location Cytosol Macrophage vesicles Extracellular fluid 
Effector T cell Cytotoxic CD8 T cell CD4 Th1 cell CD4 Th2/Th1 cell 
Antigen 
recognition 
Pepetide: MHC class I 
on infected cell 
Pepetide: MHC class II on 
infected macrophage 
Pepetide: MHC class II 
on antigen-specific B cell 
Effector action Killing of infected cell Activation of infected 
macrophages 
Activation of specific B 
cell to make antibody 
 
1.1.3 Surface molecules on leukocytes  
Communication among cells of the immune system, and between cells of the 
immune system and those of the blood-tissue barrier or target cells, is a prerequisite 
for efficient and well-ordered immune responses that comprise lymphocyte trafficking, 
  





T cell recognition and activation, as well as effector lymphocyte function. The 
communication can be achieved by soluble factors (such as cytokines, antibodies) or 
cell surface molecules. The study of leukocyte cell surface molecules and the 
interactions between these molecules provides insight into the mechanisms of 
immunological phenomena. 
Leukocyte surface molecules are named systematically by assigning them a 
cluster of differentiation (CD) antigen number that includes any antibody having an 
identical and unique reactivity pattern with different leukocyte populations. The 
number of CD antigens identified on leukocytes has been more than 350 by 2004 due 
to the progress in the monoclonal antibody technology [7]. 
T cell surface molecules can be grouped into co-stimulatory molecules, adhesion 
molecules and co-receptors depending on their functions. There are overlaps between 
these subgroups. For example, CD28 is both an adhesion molecule and a 
co-stimulatory molecule, which delivers a signal required for T cell activation when 
bound to its ligands B7 (CD80 or CD86) on APCs. CD4/CD8 serve as both adhesion 
molecules and co-receptors by binding to MHC. The adhesion molecules such as 
LFA-1 (binding to ICAMs) and CD2 (binding to CD58) strengthen the adhesion 
between T cells and APCs or target cells. T cells also express receptors for various 
cytokines (such as IL2) that regulate cell growth and differentiation [7]. 
T cell surface molecules are important for T cell activation, a complex process 
involving multiple ligand-receptor molecular interactions between T cells and APCs 
(Figure 1-1). It is believed that at least two distinct signals are required for full T cell 
  





activation. The antigenic signal (signal 1) is generated upon interaction of TCR with 
pMHC complexes, and co-stimulatory signals (signal 2) are delivered by adhesion and 
accessory interactions such as CD28/B7, LFA-1/ICAM-1 and CD2/CD58. T cells that 
receive signal 1 in the absence of signal 2 may become unresponsive to these antigens 
or only be partially activated. The microenvironment in which T cells engage their 
antigen can determine the types of cytokine secreted. Therefore, although triggered by 
the primary signal, the outcome of T cells, either a proliferation response or the 
induction of an immunological tolerance, depends on the further signals from these 
adhesion/ co-stimulatory molecules and growth factor receptors [8, 9]. 
 
Figure 1-1 Molecular interactions at the interface of T cells and APC. Signal 1 is provided by 
the interaction between TCR and MHC-peptide complex. Signal 2 is delivered by pairs of 
adhesion and co-stimulatory molecules.  
1.1.4 Cell adhesion molecules (CAMs) 
Cell adhesion molecules (CAMs) mediate the binding of one cell to other cells or 
to extracellular matrix proteins. Integrins, selectins, and Ig superfamily (IgSF) are 
  





three major types of CAMs critically involved in multiple aspects of immune 
function.  
Integrins are a large family of heterodimeric cell-surface receptors with 
noncovalently linked α and β chains. Integrin ligands include extracellular matrix 
proteins such as fibronectin, laminin, collagen, and fibrinogen, as well as cell-surface 
molecules such as intercellular adhesion molecules (ICAMs) and vascular cell 
adhesion molecules (VCAMs). The lymphocyte function-associated molecule 1 
(LFA-1, αLβ2, CD11a/CD18), the most widely studied β2 integrin, play important 
roles in leukocyte adhesion and antigen presentation [10,11]. 
Many of the T cell adhesion molecules belong to IgSF, including ICAMs, 
VCAMs, TCR, MHC antigens, CD2, CD3, CD4, CD8. These adhesion molecules 
typically have a large amino-terminal extracellular domain, a single transmembrane 
helical segment, and a cytoplasmic tail. IgSF molecules bind either to other IgSF 
members (e.g. MHC-TCR, CD2-CD58) or to integrins (e.g. LFA-1/ICAM-1) [11]. 
CAMs play important roles in leukocyte trafficking and T cell activation. 
Leukocytes migrate extensively throughout the body to mediate immune surveillance 
and to mount inflammatory responses to foreign antigens. During the early phase of 
inflammation, leukocytes and activated endothelial cells express selectins that mediate 
a weak and unstable leukocyte-endothelial interaction (leukocyte rolling), and this 
stage leads to activation of the integrins. Strong and firm adhesion is then mediated by 
leukocyte integrins that bind to their counter receptors (IgSF members such as ICAMs) 
on endothelium. Leukocytes then migrate across this barrier to the inflammatory sites, 
  





where Ag recognition and T cell activation are completed through heterotypic 
interactions between co-stimulatory/adhesion molecules (mostly IgSF members) on 
leukocytes and target cells [11].  
1.2 Modulation of the immune response 
The immune system, especially the adaptive immunity, has evolved to become 
more specific, complex, efficient, and regulated to protect the host from infection and 
therefore maintain normal health. Unfortunately, adaptive immune responses are 
sometimes elicited by some antigens not associated with infections and may cause 
serious diseases. For example, certain environmental antigens may cause allergic 
diseases and hypersensitivity reactions. Only different in the antigens, these responses 
are essentially identical to adaptive immune responses to infectious antigens. Much of 
the attention has been made to the responses to two particularly important categories 
of non-infectious antigens: responses to self-antigens, called autoimmunity, which can 
lead to auto-immune diseases; and responses to alloantigens on the transplanted 
organs that result in graft rejection [1].  
1.2.1 Self-tolerance and auto-immune diseases 
The immune system normally acquires self-tolerance by clonal deletion or clonal 
anergy of autoreactive T cells in the thymus during the perinatal period and by 
functional suppression of autoreactive T and B cells at later stages of development [1]. 
Nevertheless, sometimes a failure in the maintenance of self-tolerance may ultimately 
develop into auto-immune diseases, in which T cells specific for self antigens can 
  





cause direct tissue injury (by activation of CTL or macrophages) and have a role in 
sustained autoantibody responses (by activation of self-reactive B cells) [8, 12].  
There are more than 80 recognized auto-immune diseases that are generally 
classified on the basis of the organ or tissue involved. Auto-immune diseases can 
affect one (localized) or more organs (systemic) in the body, including nervous, 
gastrointestinal, and endocrine systems as well as skin and other connective tissues. 
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are the most 
studied systemic auto-immune diseases, while multiple sclerosis (MS), 
insulin-dependent diabetes mellitus (IDDM) and thyroiditis are the most investigated 
organ specific auto-immune diseases [1]. Many of auto-immune diseases are chronic 
and potentially life-threatening. For example, RA affects approximately 0.8 percent of 
adults worldwide, three-quarters of whom are women [13]. It has been reported that 
80 percent of RA affected patients are disabled after 20 years, and life expectancy is 
reduced by an average of 3 to 18 years [14]. 
Although the cause of auto-immune diseases is not fully known, it is widely 
accepted that auto-immune diseases result from the action of environmental factors on 
a predisposed genotype. The fact that auto-immune diseases tend to occur in families 
convinced researchers that some genes increase vulnerability or susceptibility to 
auto-immune diseases. Further studies have shown the association between certain 
HLA (MHC in human) types and auto-immune diseases. On the other hand, 
considerable evidence supports that environmental factors, including infection, 
climate, lifestyle (smoking or coffee intake), stress and trauma, hormonal exposure, 
  





play an important role in inducing or flaring some auto-immune diseases like RA and 
SLE [1, 15]. 
1.2.2 Transplantation and graft rejection 
The transplantation of tissues to replace diseased organs is now an important 
medical therapy and a variety of organs (such as kidney, liver, heart, bone marrow) are 
transplanted routinely. Rejection, the major impediment to successful transplantation, 
is caused by immune responses to alloantigens on the graft, which are proteins that 
vary from individual to individual and are therefore perceived as foreign by the 
recipient. Recipient’s T cells are stimulated by either donor APC with allogeneic 
MHC molecules, or allogeneic peptides processed by recipient APC with self MHC 
molecules. Alloreactive T cell responses to the MHC molecules almost always trigger 
a response against the grafted organ. The syndromes of rejection are in many ways 
similar to auto-immune disease, and T cells are the main effectors in graft rejection 
[1]. 
Although HLA matching significantly improves the success rate of clinical organ 
transplantation, it does not prevent rejection reactions because of the genetic 
differences in major or minor histocompatibility antigens between donors and 
recipients. Thus, unless donor and recipient are identical twins, all graft recipients 
must be given immunosuppressive drugs to prevent rejection even if the tissues are 
well matched. In fact, the current success in solid organ transplantation is more the 
result of advances in immunosuppressive therapy than of improved tissue matching 
  





[1]. The powerful immunosuppressive drugs, especially cyclosporin A [16] and 
tacrolimus [17] that inhibit T-cell activation, have been widely used in organ 
transplantation. 
1.2.3 Biological agents for treatment of immunological disorders 
Tolerance, the regulated inability to respond to a specific immunologic stimulant, 
is a physiological event important to normal immune function. There are two 
important mechanisms of tolerance: clonal deletion by ubiquitous self antigens and 
clonal inactivation of tissue-specific antigens presented in the absence of 
co-stimulatory signals [1]. Since both auto-immune diseases and graft rejection target 
tissue-specific antigens, a major therapeutic goal for the treatment of these 
immunological disorders is to achieve or induce immunological tolerance. 
Conventional immunosuppressive drugs, including anti-inflammatory drugs 
(steroids or non-steroidal anti-inflammatory drugs (NSAIDs)), cytotoxic drugs (such 
as azathioprine and cyclophosphamide) as well as fungal and bacterial derivatives 
(cyclosporin A, tacrolimus) are used as routine regimen to treat auto-immune diseases 
or increase graft survival rates. However, these nonspecific drugs impose numerous 
undesirable side effects and often result in chronic rejection due to lack of the 
tolerance induction ability. Therefore the ideal immunosuppressive agents would 
target the specific process of the immune response and at meantime achieve long-term 
immune modulation [1, 18].  
Our increasing understanding of the pathophysiology of auto-immune disease 
  





has revealed a number of checkpoints that can be targeted with immunotherapy, such 
as key mediators of lymphocyte adhesion and migration and destructive cytokines 
involved in tissue damage [19]. T cell co-stimulatory and adhesion molecules have 
become attractive targets due to their important roles in determining possible T cell 
outcomes (activation, tolerance or death). For example, it has been demonstrated that 
CD2 co-stimulation induced the differentiation of non-proliferating regulatory T cells, 
which may result in T cell anergy or tolerance, and CD2 mAb can induce long-term 
tolerance in mouse and rat models of transplantation [20]. Tolerance induction can be 
achieved even more easily through the combined blockade of two or more 
co-stimulatory pathways [18]. Cytokines and their receptors has become another 
therapy target since numerous evidence indicated their involvement in some 
auto-immune diseases (such as RA, MS, psoriasis) as well as transplantation rejection 
[21]. 
Monoclonal antibodies (mAbs), mainly targeting T cell adhesion molecules or 
cytokines, are potentially powerful immunosuppressive agents due to their specificity 
and precise manipulation of the immune response as well as the ability to induce 
immunological tolerance [8, 18]. Humanized Abs, chimeric Abs and fusion proteins 
have proved efficacy in treating auto-immune diseases and organ transplant rejection 
(Table 1-2). Inhibitors of different adhesion molecules (such as CD3, CD4, CD28, 
CD2, LFA-1 and CTLA-4) have been successfully developed into immunosuppressive 
agents for auto-immune diseases or allograft rejection [12, 22, 23, 24]. The 
antagonists against tumor necrosis factor (TNF) and interleukin-2 (IL-2) are widely 
  





used for RA and transplantation rejection respectively [21]. 
 
Table 1-2 Antibody therapy for auto-immune diseases and organ transplantation. Inhibitors of 
adhesion or co-stimulatory molecules and cytokine antagonists are therapeutically important 
immunosuppressive agents [12, 21, 22, 23, 24]. 
 
Compound Type Target Indications 
Muromonab-CD3 
(Orthoclone OKT®3)  
anti-CD3 mAb TCR-CD3 
complex  
FDA approval for solid 
organ transplant 















FDA approval for chronic 








FDA approval for plaque 
psoriasis and progressive 
psoriatic arthritis (PsA). 
Abatacept  CTLA-4-Ig chimeric 
protein 
CD80/CD86  Expected to be approved 
by FDA for RA  
IDEC-114  anti-CD80 mAb CD80 Phase II clinical trial for 
plaque psoriasis and RA 
Basiliximab 
(Simulect ®)  
 
anti-IL-2 receptor 
(CD25) chimeric mAb 
IL-2 receptor FDA approval for acute 







IL-2 receptor FDA approval for acute 




TNF receptor- IgG1 
fusion protein 
TNF receptor FDA approval for RA 
Infliximab 
(Remicade®)  
chimeric mAb to 
TNF-α 
TNF-α FDA approval for Crohn's 
disease and RA. 
Adalimumab 
(Humira®) 
humanized mAb to 
TNF 
TNF FDA approval for RA 
1.3 Targeting CD2/CD58 interaction for immunomodulation 
CD2 is one of the best characterized adhesion molecules mediating immune 
response and has emerged as an attractive target for immune modulation. Modulation 
  





on the interaction between CD2 and its ligands may be therapeutically useful for 
allograft rejection and auto-immune diseases.  
1.3.1 CD2 structure  
CD2, also known as T11, LFA-2 or SRBC (sheep red blood cells) receptor, is a 
50 kD transmembrane glycoprotein found on T cells, thymocytes and NK cells. CD2 
consists an extracellular region and a proline-rich cytoplasmic domain. The 
cytoplasmic domain is considerably conserved in different species (humans, rats and 
mice) and important for signal transduction. Several transducing enzymes and adapter 
proteins have been shown to interact with the intracellular portion of CD2 [25]. 
NMR and crystallographic studies of extracellular regions of rat CD2 (rCD2) and 
human CD2 (hCD2) revealed the ectoregion consists of four parts: a V-set IgSF 
domain (domain 1, D1), a C2-set IgSF domain (domain 2, D2), a linker and a stalk. 
Despite a low sequence homology (45%), the core structures and topology of 
extracellular regions of hCD2 and rCD2 are quite similar [26, 27, 28]. D1, also called 
the N-terminal domain, is responsible for the adhesion function, whereas D2 connects 
D1 to the membrane. The crystal structure of rCD2 D1 revealed that nine β strands 
sandwiched in two β sheets of AGFCC’C’’ and BED with four well-defined hairpin 
structures of CC’, C’C’’, FG and DE (Figure 1-2 (a))[29, 30]. NMR and X-ray 
crystallography studies confirmed that hCD2 D1 has the same topology (Figure 1-2 
(b)) [26, 27]. 
Molecular and functional studies of hCD2 identified 3 distinct epitopes on T and 
  





NK cells that are responsible for ligand binding (T111) or activation function (T112 
and T113) [25]. Anti-T111 mAb binds to CD2 D1 and blocks adhesion to CD58, while 
anti-T112 maps to D1 but at a site orthogonal to the GFCC'C" face. T113, also termed 
CD2R (CD2-restricted epitope), however, is mapped to the flexible CD2 linker region 
between D1 and the membrane-proximal extracellular domain (D2). The 
ligand-mediated conformational change within CD2 ectodomain (D1-D2) exposes 
CD2R, facilitates packing of CD2 molecules in a clustered array and is linked to 
CD2-mediated adhesion and activation events [31]. 
 
Figure 1-2 Topology of domain 1 of CD2 and CD58. (a) Crystal structure of rCD2 D1 [30]  (b) 
human CD2 D1[27, 33] and (c) NMR structure of CD58 D1 with 6 mutations [33, 34]. 
1.3.2 CD2 ligands and ligand binding sites 
The first CD2 ligand identified was CD58 (lymphocyte function-associated 
antigen 3, LFA-3), which, in humans, is widely expressed on hematopoietic and 
nonhematopoietic cells as a transmembrane (TM) or glycosyl phosphoinositol 
(GPI)-linked surface glycoprotein [32]. CD58 exhibits 21% amino acid homology as 
  





CD2, and its extracellular region also consists two IgSF domains with the domain 1 
responsible for adhesion [28, 33]. Both NMR [34] and X-ray structures [35] of CD58 
D1 revealed extremely similar topology (Figure 1-2 (c)) as CD2 D1, and the mutation 
study mapped CD2 binding site to the GFCC'C" β sheet of CD58. 
However, no rodent homologue of CD58 has been found, while the structurally 
related molecule CD48 has been identified as the CD2 ligand in mice and rats [28]. It 
has been reported that CD48 is a low affinity ligand for hCD2 with a ～100 fold 
weaker binding constant than that of CD58 and unable to support cell based adhesion. 
These findings suggest a divergence of functional CD2 ligands from CD48 to CD58 
during the evolution as a result of gene duplication [36]. 
CD2 and its ligands (CD58 and CD48) belong to the CD2 subset of IgSF that 
consists at least 11 members. Studies suggest that these structurally related proteins 
evolved from a common, homophilic precursor [28, 37]. 
1.3.3 Properties of CD2-ligand interactions 
The interaction of CD2 and its ligands is characterized by relatively low affinity 
(kd=10-20µΜ for hCD2-CD58 and kd=60-90µΜ for rCD2-CD48) that is 
approximately 105 fold weaker compared to antigen-antibody or proteinase-inhibitor 
interactions. The low affinities are thought to be associated with extremely rapid kon 
(>105M-1s-1) and koff (≥4s-1) rates that allow transient and reversible cell-cell 
adhesion [28,37,38].  
Quite different from high-affinity protein-protein interactions, this weak but 
  





specific interaction can mediate cell-cell adhesion in antigen recognition and T cell 
activation. Quantitative fluorescence imaging of the binding of cell surface human 
and rat CD2 with their fluorescently labeled GPI-anchored ligands (CD48 and CD58) 
indicated that the low affinity CD2/ligand interactions cooperate to align membranes 
with nanometer precision leading to a physiologically effective two-dimensional 
affinity [39]. Interaction between CD2 expressing T cells and glass-supported 
fluorescently labeled CD58 indicated a rapid recovery of the accumulated fluorescent 
CD58, which demonstrated that the CD2-CD58 bonds are transient and the rapid 
dissociation leads to partner exchange, rather than rebinding of the same CD2-CD58 
pairs [40]. 
There are two features of CD2-ligand interface that make it unusual as a site of 
protein-protein recognition. Firstly, the surface of the binding site is relatively flat 
with poor shape complementarity. The average distance of surface atoms from the 
least-squares plane defining the GFCC'C" face in human sCD2 is approximately 1.8 Å, 
and 1.6 Å in rat CD2. Secondly, the face has a large number of charged residues. 
rCD2 and hCD2 contain 45% and 70% of the charged residues on the GFCC’C’’ 
interface, which is significantly more charged than the ligand binding sites of most 
proteins (29%)[27].  
1.3.4 Structural basis for CD2-ligand interactions 
Numerous studies, including mutagenesis studies, NMR as well as X-ray 
crystallograph have provided key insights into the structural basis of CD2-ligand 
interactions. 
  





The “head-to-head” crystal contact found in rCD2 and hCD2 homodimers has 
been proposed as an interaction model for CD2 with its ligands. The complementary 
mutagenesis on rCD2 and CD48 has provided strong support for this head-to-head 
model and suggested a spanning distance similar to that in TCR-pMHC complex 
(around 135Å) [41]. The NMR titration and site-directed mutation studies of rCD2 
and CD48 mapped the interaction interface to GFCC’C’’ β sheets on D1 of each 
molecule [41, 42]. Later, the head-to-head orientation of rCD2-CD48 has been 
directly demonstrated using surface force apparatus (SFA) [43, 44]. However, crystal 
structure of rCD2-CD48 complex has not been solved possibly due to the weak 
affinity of this interaction. 
Crystal structures of hCD2 [27] and CD58 [35] also suggested the head-to-head 
interaction involving GFCC’C’’ faces from both molecules. The most direct 
visualization of the interaction between hCD2 and CD58 was provided by the crystal 
structure of the complex [45]. Wang et al [45, 46, 47] have determined that hCD2-D1 
and CD58-D1 pack face-to-face with their GFCC’C’’ β sheets in a “hand-shaking” 
fashion (Figure 1-3). The CD2-CD58 interface is highly asymmetrical due to not only 
the poor shape complementarity but also the asymmetrical distribution of charged 
interface residues, dominantly basic and acidic charged residues on CD2 and CD58 
respectively [45, 46, 47]. The observed interface between CD2 and CD58 by X-ray 
crystallography correlates well with mutagenesis studies [48, 49] and NMR studies 
[26, 34].  
 
  







Figure 1-3 Ribbon drawing of the hCD2/hCD58 interface. hCD2 is in blue and hCD58 is in 
yellow. The β strands in both molecules are labeled in black [45]. 
Considerable attention has been focused on interface residues, especially the 
charged ones to map the ligand binding epitopes on CD2. The mutational and 
electrostatic-screening studies identified eight charged or polar residues (D28, E29, 
R31, E33, E41, K43, T86, and R87), two aromatic (F49 and Y81) and one aliphatic 
(L38) in rCD2 ligand binding site. These charged residues contribute little or no 
energy to CD48 binding, while F49, Y81 and L38 are the source of most of the 
ligand-binding energy thus they serve as the functional epitope. However, the binding 
specificity was severely compromised by alanine mutagenesis of these charged 
residues [50]. It is therefore believed that the favorable electrostatic complementarity 
merely compensates for the unfavorable removal, upon binding, of water bound to 
charged residues with little contribution to binding energy of rCD2-CD48 [7, 37]. 
This can also be used to explain the relatively low binding affinity of rCD2-CD48 
compared to hCD2-CD58. 
Similarly, a large number of charged or polar residues, ten from hCD2 and 
twelve from CD58 are involved in forming ten salt bridges and five hydrogen bonds 
  





at hCD2/hCD58 interface (Figure 1-4 (A)). These electrostatic interactions not only 
ensure high co-ligand specificity, but also contribute binding energy because the 
unfavorable like-charge residues clustering in each binding surface will be neutralized 
upon complex formation. Furthermore, the charged residues form a hydrophilic area 
that excludes solvent from the interface thus stabilizing the complex [45]. Therefore, 
these charged residues are critical for ligand binding and alanine mutation of some 
charged residues on CD2 interface resulted in loss of CD2-CD58 adhesion (Figure 1-4 
(B)) [51].  
 
Figure 1-4 Charged residues in the hCD2-hCD58 interface. (A) The positive residues (in dark 
blue) and negative residues (in deep red) involved in salt bridge interactions are labeled [45]. 
(B) The CD2 residues involved in the CD58 binding are labeled and colored based on 
mutation results and their effects on CD2-CD58 interaction. Mutations D31A, K34A, K43A, 
K51A and N92A (in brown) had a stronger effect, reducing the adhesion more than 50% and 
CD58 binding more than an order of magnitude; mutations D32A, R48A, and K91A (yellow) 
abolished adhesion completely and manifesting a 47～127-fold decrease in CD58 binding 
affinity. The Y86A (red) mutation resulted in loss of binding to CD58 more than 1000-fold. 
The CD58 key residues K34 and F46 are labeled [51]. 
  





On the other hand, only three hydrophobic residues (F46 and P80 from CD58 
and Y86 from CD2) are found to interact between CD2-CD58. The aromatic rings 
from F46 of CD58 and Y86 of CD2 sandwich the aliphatic component of the K34 
CD58 side-chain, thereby creating a small but critical hydrophobic core that 
contributes significantly to the energy and stability of the complex (Figure 1-5). 
Therefore, mutation of the energetic hot spot residue Y86 (Y86A) reduced CD58 
binding affinity by 1000 fold [47]. 
 
 
Figure 1-5 The energetic hot spot and its surroundings in the hCD2-hCD58 interface. The 
CD2 is in gray and hCD58 is in green. The yellow labels mark the relevant β strands. The 
broken lines represent hydrogen bonds [47]. 
In summary, electrostatic interactions on CD2-ligand interfaces likely contribute 
to the fast on-rate and high binding specificity. On the other hand, poor shape 
complementarity resulting from the shortage of hydrophobic contact leads to the low 
  





binding affinity and rapid off rate. Different from high-affinity protein-protein 
interactions in which a more hydrophobic interface with high shape complementarity 
contributes to the binding affinity and specificity, this electrostatic interaction that 
uncouples increase in binding specificity from increase in binding affinity is ideally 
suitable for mediating weak but specific protein recognition important for cell 
adhesion and cell-cell recognition [7,28,37,45]. Therefore, CD2–CD58 interface 
offers insights into interactions of other IgSF receptors as well as provides a new 
target for rational design of immunosuppressive agents. 
1.3.5 Role of CD2/CD58 interaction in T cell activation 
In contrast to conventional leukocyte cell adhesion molecules (such as integrins 
and selectins) that are important in locomotion and tissue homing, CD2 plays an 
important role in mediating antigen-dependent or antigen-independent T cell 
activation with dual functions of adhesion and signal transduction [28].  
In the “classical pathway” of antigen-dependent activation, CD2-CD58 
interaction enhances TCR-pMHC interaction and contributes to the accessory signals 
needed for T cell activation. Numerous studies have shown that anti-CD2 mAb can 
inhibit MHC-restricted antigen recognition by blocking T cells adhesion to APCs or 
target cells. Both CD2 and CD58 mAbs can inhibit Ag-dependent Th cell proliferation 
and CTL-mediated killing by binding to T cells and target cells respectively [25, 28]. 
Moreover, anti-CD2 and anti-CD48 antibodies were found to impair cytokine (IL-2 
and IFN-γ) synthesis that is critical for proliferation and cytotoxic function of CTLs 
  





[52]. On the other hand, specific combination of mAb to certain CD2 epitopes 
(T112/T113) can result in proliferation in the absence of Ag, termed as “alternative 
pathway” of T cell activation [25]. 
CD2-CD58 interaction shares some common features with TCR-pMHC 
interaction, implying the importance of CD2 pathway in antigen recognition. Both 
CD2- and TCR-ligand complexes display poor surface-shape complementarity and 
low binding affinity [7, 37, 38]. Direct force measurement of CD2/CD48 adhesion has 
confirmed that CD2-ligand complex spans an intermembrane gap of 130～135 Å, 
similar to the dimension of TCR-pMHC complex [43]. These features suggest that 
CD2 adhesion pathway is independent on TCR engagement and fosters the initial 
stages of cell contact even prior to TCR recognition of pMHC molecules. 
During the earliest stage of T cell and APC contact, the ligation of CD2 by CD58 
creates an intercellular membrane distance (≈135 Å) ideal for TCR–MHC complex, 
allowing TCR diffuse into the contact space and interact with pMHC, while larger 
molecules such as inhibitory CD45 or integrins being excluded from this junction to 
ensure the low-affinity TCR-pMHC interaction [53]. Meanwhile, the low affinity and 
rapid dissociation rate between CD2 and CD58 allows the movement of T cells along 
APCs referred to as T cell scanning, which facilitates the scanning of appropriate 
pMHC by TCR. T cell polarization, which is characterized by the formation of a 
leading edge at the front of the cell and a uropod at its back, is required for T cell 
migration in immune surveillance. The uropod mediates important adhesion functions 
due to the accumulation of various adhesion molecules, while the leading edge 
  





propels the cell forward. It has been found that surface CD2 molecules rapidly 
redistribute on interaction with the CD58, resulting in a 100-fold greater CD2 density 
in the uropod along with the TCR and lipid raft microdomains. This highly specified 
redistribution process prearranges the activation machinery for subsequent pMHC 
recognition [54]. CD2-CD58 interaction has been shown to be mandatory for 
large-scale molecular segregation at the T cell-APC contact site and for full T cell 
activation [53]. In the presence of CD2-CD58 interaction, T cells recognize correct 
pMHC with a 50-to 100-fold greater efficiency than in the absence of this interaction 
[45].  
1.3.6 Involvement of CD2/CD58 interaction in disease pathology 
Adhesion molecules that mediate leukocyte adhesion and transendothelial 
migration play an important role in the pathogenesis of inflammation and immune 
disorders. Activation of certain adhesion molecules within vascular endothelium and 
the surrounding extravascular space is a critical event in the recruitment and targeting 
of an inflammatory response or auto-immune attack to a particular tissue site, which 
makes certain adhesion molecules useful in disease diagnosis and monitoring [10,11]. 
Studies carried out on adhesion molecules in the past few years have shown the 
association of soluble adhesion molecules with various diseases. For example, 
elevated soluble forms of adhesion molecules such as sICAM, sVCAM and 
sE-selectin have been detected in the sera of patients with malignancies, inflammatory 
diseases as well as auto-immune diseases. These soluble adhesion molecules may be 
  





clinically useful as indicators of the inflammatory process and may provide some 
insight into treatment of these diseases [55, 56, 57]. 
Adhesion molecule CD2 and ligand CD58 are involved in T cell interactions 
with other cell types, such as B cells, monocytes, neutrophils as well as endothelial 
cells, suggesting CD2/CD58 involvement in the pathogenesis of inflammation or 
immune diseases. CD58 was up-regulated on various cell types in the oral form of 
lichen planus (OLP), and may play an important role in the pathology of this chronic 
inflammatory disease characterized by the accumulation of T cells below the basal 
layer of the buccal mucosa [58]. The overexpression of CD58 in precursor-B acute 
lymphoblastic leukemia (ALL) blasts than in normal B lymphocytes confirmed the 
role of CD58 in the diagnosis and monitoring of precursor-B ALL [59]. Over 
expression of CD58 (LFA-3) was found to induce higher secretion of TNF and IL-2 
produced by specific CTLs, suggesting a high LFA-3 expression by tumor cells may 
be critical for the success of anti-tumor immune responses [9]. Increased level of 
soluble CD58 (sCD58) was found in malignant pleural effusions, which may either 
limit the extent of inflammation or alternatively, inhibit the effective cytolysis of 
tumor cells by Tc or NK cells via interfering with cell-cell adhesion [60].  
Rheumatoid arthritis (RA) is a chronic systemic auto-immune disease that is 
characterized by joint swelling which results from leukocyte recruitment into synovial 
tissue. The finding that both CD2 and CD58 are up-regulated on synovial fluid (SF) 
mononuclear cells supported the notion that CD2/CD58 interaction is involved in 
rheumatoid synovitis. Furthermore, the reduction of serum sCD58 was found in 
  





patients with RA and correlated significantly with clinical disease activity. Since 
locally released sCD58 blocks the CD2/CD58 interaction under physiological 
conditions, insufficient release of sCD58 may result in increased T cell activity and 
perpetuation of inflammation [61,62]. 
1.3.7 Therapeutic potential of CD2 and its ligands 
Better understanding of the critical roles of CD2/CD58 interaction in immune 
regulation and disease pathology has provided new targets for potential 
immunosuppressive agents.  
Studies by Cahen and colleagues suggested the inhibitory effects of 
glucocorticoids and retinoids for OLP treatment result from the down-regulation of 
LFA-3 on cells [58]. Alefacept (Biogen Inc., USA), a soluble CD58-Ig fusion protein 
designed to disrupt the T-cell activation process via interrupting CD2-CD58 
interaction has been approved by U.S. Food and Drug Administration (FDA) to treat 
plaque psoriasis [63]. Alefacept showed clinical efficacy in reducing the signs and 
symptoms of joint inflammation in patients with psoriatic arthritis [64, 65].  
The rat antihuman CD2 mAb, BTI-322 and its humanized version MEDI-507, 
effectively inhibited the primary xenogeneic MLR in vitro, suggesting the potential of 
the CD2 mAb for tolerance induction and T cell depletion in vivo [66]. BTI-322 was 
found effective in renal allograft tolerance and acute GVHD in clinical studies [67], 
while MEDI-507 is now being studied in the treatment of certain lymphoproliferative 
disorders and psoriasis [22]. It is therefore conceivable that more therapeutic agents 
  





based on CD2 and its ligands CD58 will be developed in the future. 
The recent advance in the understanding of the pathogenesis of RA has generated 
many potential biological agents for the treatment of RA, including monoclonal 
antibodies that target proinflammatory cytokines (TNF-α or IL-1), co-stimulatory 
blockage agents that block T cell activation and induce anergy (such as CTLA-4-Ig 
fusion protein), lymphocyte migration and recruitment inhibitors by blocking 
intercellular adhesion molecules (such as anti-ICAM-1 mAb), as well as vaccines and 
gene therapy [23, 68, 69]. Although TNF-α antagonists show the most effective results, 
other agents also have therapeutic implications and may play an adjunct therapeutic 
role. CD2 is expected to be a potential target in RA treatment as CD2-CD58 
interaction is thought to be involved in pathogenesis of RA. Furthermore, as an 
important adhesion and co-stimulatory molecule, biological agents targeting CD2 may 
exert the immunosuppressive effects by the mechanism of T cell anergy, inhibition of 
lymphocyte migration, or both.  
1.4 Peptide-based drug design for immunomodulation 
The antibody therapy has many restrictions including poor patient compliance in 
long-term therapy, inherent immunogenicity and susceptible to proteolytic 
degradation. Therefore, an alternative therapeutic approach for auto-immune diseases 
and allograft rejection is small peptide-based agents (such as peptides, 
peptidomimetics) that will specifically target adhesion molecules and meantime 
circumvent the problems associated with antibody-based therapy [12]. 
  





1.4.1 β-turn as drug design target 
α-helices, β-sheets and β-turns are major secondary structures stabilizing protein 
conformation. In order to connect the strands in β-sheets or join helices and sheets in 
various combinations, protein must contain turns that allow the peptide backbone to 
fold back and thus keep proteins in compact shape. 
A β-turn is a region involving four consecutive residues where the polypeptide 
chain folds back on itself by nearly 180 degrees. In conventional Venkatachalam 
nomenclature, classic β-turns possess the intra-turn hydrogen bond (IHB) between the 
carbonyl oxygen atom of the first residue (i) and the amide NH proton of the fourth 
residue (i+3) to give a pseudo-10-membered ring (Figure 1-6). The most widely used 
Richardson nomenclature introduces additional classification criteria that the distance 
between Cα (i) and Cα (i+3) is <7Å and the residues involved are not helical, thus 
extends the types of β-turns by including open β-turns without IHB. β-turns have been 
classified into 9 different types (I, II, VIII, I’, II’, VIa1, VIa2, VIb, IV) based on the 
dihedral angle values (φ, ψ) of the residues in the second (i+1)and third (i+2) position 
in the turn. Τype I and type II are most common IHB turns in globular proteins, while 
type VIII is the most common non-classic β-turns [70]. The mirror image types (I' and 
II') without IHB are frequently observed in β-hairpins and believed to promote 










Figure 1-6 Schematic representation of typical β-turn with intra-turn hydrogen bond between 
C=O (i) and N-H (i+3). 
In addition to the importance in maintaining protein structure, β-turns also 
present a useful target for drug design. Because turns or loops usually occur on the 
exposed surface of proteins and hence probably represent receptor binding sites or 
participate in molecular recognition, drugs mimicking these important turns or loops 
can modulate the protein function. For example, a cyclic heptapeptide 
cyclo(CNSNQIC) based on CD4 D1 CC’ loop can mimic the β-turn of native CD4 
CC’ loop and thus inhibit CD4 biological function [72]. Since some other IgSF 
members (such as CD8, CD2 and CD28) also have structurally similar domains and 
similar functional epitopes as in CD4, this study suggested a general peptide-based 
approach for modulation of protein-protein interaction by targeting important β-turn 
structure [27, 72]. 
Since most small linear peptides are highly flexible and do not adopt stable 
solution conformations as the same sequence adopts in native proteins, cyclization is a 
useful approach to improve the peptide conformation stability and thus improve the 
binding affinity to ligands by mimicking native turns or loops on protei
  





Cyclization would also increase both plasma stability and potency of linear peptides. 
Therefore, cyclized peptides or chemically modified peptidomimetics may serve as 
attractive candidates with high bioavailability, metabolic stability, functional 
specificity and potent activity [73]. A small disulfide constrained β-hairpins (CX8C) 
was introduced by Cochran et al as scaffolds for β-turn display, which is expected to 
structure a large number of four-residue sequences into β-turns for peptide-based drug 
discovery [74]. 
1.4.2 Peptide design from protein interaction interfaces 
Despite that protein-protein interactions generally involve large interfaces with 
many intermolecular contacts, recent studies indicate that proteins may actually 
interact through small surface binding epitopes. Identifying these binding epitopes is 
not only important for understanding the mechanism of protein-protein interaction, 
but also helpful in rational or structure-based drug design.  
Anatomy of protein interfaces has further indicated that the free energy of 
binding is not evenly distributed across interfaces. Instead, there are hot spots of 
binding energy made up of a small subset of residues enriched in tryptophan, tyrosine 
and arginine. These hot spot residues are surrounded by energetically less important 
residues that most likely serve to occlude bulk solvent from the hot spot, which is a 
necessary condition for highly energetic interactions [75].  
Therefore, binding epitopes and hot spots on protein interfaces have implications 
in peptide design to mimic or modulate protein-protein interactions. Mimics of such 
  





small binding epitopes may be sufficient to block a large protein-protein interface. For 
example, the interface peptides with the same sequence as key regions at the interface 
can modulate the protein-protein interactions [72,76]. A cyclic peptide mimicking 
C-D loop of VCAM-1 that is critical for ligand binding can inhibit binding of α4β1 
integrin-bearing cells to VCAM-1 [77]. 10-amino acid short peptides designed from 
the contact domains of LFA-1 and ICAM-1 were effective at inhibiting intercellular 
adhesion, T cell activation as well as T cell proliferation in the mixed lymphocyte 
reaction [78]. More importantly, these potentially effective peptides are useful for the 
development of peptide-based therapeutic agents (such as peptidomimetics), because 
pseudopeptides with altered peptide bond are less susceptible to natural proteases, 
which is a major limitation for peptide therapy [79].  
1.4.3 Design from CD2 epitopes for modulation of CD2-CD58 interaction   
Due to the important roles in T cell activation, many IgSF adhesion molecules 
(such as ICAM-1, VCAM-1, CD4, CD8) have long been used as the targets for 
immunosuppressive agents design [72,77, 80, 81]. However, less attention has been 
focused on CD2 that is widely involved in immune response and immune disease 
pathology, a possible reason of which lies in that the crystal structure of CD2-CD58 
complex has not been resolved until 1999 [45].  
The strategy of targeting important interface loops or epitopes for 
immunomodulation is applicable in CD2 derived peptide design since IgSF adhesion 
molecules have structurally similar domains and share common backbone topology 
  





that are critical for protein-protein interaction [72].  
NMR studies of rCD2 have mapped CD48 binding site from CC’ to FG loop 
(Figure 1-7 (A)) [42]. Mutagenesis and binding studies by Davis et al arrived at the 
same rCD2 structural epitope for ligand binding. Since charged residues are 
responsible for the ligand binding specificity, while F49, Y81 and L38 serve as the 
functional epitope by contributing most of the ligand-binding energy [50], drug design 
targeting at rCD2 CC’ loop and FG loop, especially at the functional important 
residues may be potential in modulating CD2-ligand interaction. 
Mutagenesis studies on hCD2 and CD58 indicated that a significant number of 
charged residues and three hydrophobic residues form the interaction area involving 
mainly the C, C’ and C’’ β-strands and the FG, CC’, and C’C’’ loops (Figure 1-7 (B)) 
[48, 49]. Crystal structure of hCD2-hCD58 complex showed that the center of the 
contact area is the C, C’ stands, and the A and G edge strands curve away from this 
interface. The most closely opposed region in hCD2-hCD58 complex is between CD2 
FG loop and CD58 CC’ loop via main chain hydrogen bonding, and the energetic hot 
spots (CD2 Tyr86 and CD58 Lys34) are located in this region (Figure 1-5) [35, 45, 
47]. Furthermore, upon binding to hCD2, hCD58 changes its conformation at its C’C’’ 
and FG loops/turns to form four intermolecular salt bridges [33, 34]. Although there is 
no significant main chain alteration in hCD2 during ligand binding, the region on 
hCD2 C’C” loop centering around residue 43-46, and the region on FG loop with the 
center around residue 86-87 are critical for the interaction of hCD2 with CD58 [45] 
Therefore, drug design focused on hCD2 CC’, C’C’’ and FG loops or hot spot is 
  





expected to modulate CD2-CD58 interaction. 
Hence, due to the important roles in CD2 structure and function, CC’, C’C’’ and 
FG loops in rCD2 or hCD2 are potential targets for drug design to modulate 
CD2-CD58 interaction. In our research group, cyclic 12-amino acid (12-aa) peptides 
and hexapeptide (cEL) designed from rCD2 CC’ and FG loops effctively blocked the 
CD2-CD58 interaction in antibody binding, E-rosetting and heterotypic adhesion 
assays [51]. 
 
    
Figure 1-7 View of CD2 ligand binding epitopes. (A) CD48 binding sites on rCD2 are 
determined by NMR study. The β-strands are named A, G, F, C, C’ and C’’ from left to right. 
Residues showing the least sensitivity to sCD48 binding are shown with black circles, 
residues with intermediate sensitivity to ligand binding with gray circles, and residues with 
the most pronounced sensitivity to ligand binding with white circles [42]. (B) CD58 binding 
sites on hCD2 domain 1 are determined by mutation study. The backbone fold is indicated in 
light blue, with the major A, G, F, C, C’ and C’’ β-strands from left to right. Residues involved 









1.4.4 Peptide/protein engineering for drug design 
Protein/peptide engineering is of great interest to scientists since it can be used to 
elucidate the structure-activity relationship (SAR) and design peptides with desired 
function. Many approaches are available in identifying functional residues or domains 
in peptides or proteins, such as site-directed mutagenesis, homolog-scanning, deletion 
& insertion scanning and alanine-scanning mutagenesis. 
1.4.4.1 Truncation scanning analysis  
As modification of the sequence length may have an effect on the conformation 
of proteins or peptides thus in turn affect their biological activity, the truncation 
mutagenesis allows quick scanning of the peptide/protein sequence to identify 
boundaries of functionally important regions, such as functional domains in proteins 
or the minimum functional segments in peptides. Truncation study of the α subunit 
cytoplasmic domain of LFA-1 has demonstrated that the α subunit regulates LFA-1 
assembly and adhesion [82]. Using this approach, Zhang et al, successfully identified 
an N-terminal loop and the PSSALRE helix as the functional domains in a cyclin 
dependent kinase (Cdk5) [83].  
As deletions may cause gross conformational changes to proteins, it should be 
noted that some regions (such as loops) could tolerate small deletions/ insertions 
better than helices or sheets thus may serve as targets for mutagenesis. After the quick 
sequence truncation, the proteins or peptides can be further subjected to more refined 
analysis, such as alanine scanning mutagenesis. 
  





1.4.4.2 Alanine scanning mutagenesis 
In alanine scanning mutagenesis, each non-Ala amino acid in a protein will be 
changed to Ala, and the contribution of an individual amino acid to the protein 
function will be assessed. Ala is used for replacement due to its abundant nature and 
can be found in all secondary structures. Substitution of Ala in the sequence is least 
likely to alter the backbone conformation of peptides because of lack of charge or 
functional side groups. Alanine scanning is considered to be a higher resolution screen 
compared to other scanning mutagenesis approaches, such as homolog-scanning, 
deletion or insertion scanning mutagenesis, thus can be done after having gone 
through those scanning approaches to identify precise residue(s) critical in function 
[82].  
Alanine scanning is particularly useful in mapping functional epitopes in proteins, 
which has been demonstrated by early examples of identifying residues modulating 
human growth hormone (hGH) binding to hGH receptor [84], as well as identifying 
CD4 binding site for HIV–gp120 [85]. This technique continues to be widely used to 
detect and identify energetically “hot spot” [47, 86] or critical residues important for 
biological activity in proteins [87]. 
1.5 Hypothesis and aim of study 
1.5.1 Hypothesis  
The following conclusions can be drawn from the above discussion. Modulating 
the interaction between adhesion molecule CD2 and its ligand CD58 presents a 
  





potential in controlling auto-immune diseases (such as RA) or allograft rejection. 
Mimics of protein-protein interface or binding epitopes may be sufficient to block the 
protein-protein interaction. CD2-CD58 interface is characterized by GFCC’C’’ 
β-sheets in which CC’, C’C” and FG loops play critical roles in the interaction, and 
the β-turns stabilizing loop structures may serve as binding epitopes or recognition 
sites. Cyclic peptides derived from CD2 interface epitopes can modulate CD2-CD58 
interaction by mimicking native β-turn structure and serve as template for powerful 
peptidomimetics. 
We hypothesize that cyclic peptides designed from CD2 interface epitopes are 
supposed to modulate CD2-CD58 interaction by mimicking important β-turn 
structures and serve as lead compounds for immunosuppressive agents. 
1.5.2 Aim of study 
 Design cyclic peptides from rCD2 and hCD2 interface epitopes and optimize 
peptides by truncation and alanine scanning mutagenesis (see chapter 2). 
 Develop a specific and sensitive cell adhesion assay to evaluate CD2-CD58 
interaction (see chapter 3). 
 Determine the minimum sequence and critical residues for inhibitory activity in 
designed peptides by biological assays (see chapter 4). 
 Investigate the structure-activity relationship (SAR) by determining 
three-dimensional structures of peptides (see chapter 5).
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2.1 Peptide design strategy 
Mutagenesis and structural studies have indicated that CD2 and its ligands 
interact through the flat, highly charged GFCC’C” β-sheets of each domain 1. 
Exposed residues critical for ligand binding in CD2 are mainly located on the FG, CC’ 
and C’C’’ loops (Figure 2-1). These important surface loops were therefore 
investigated as potential leads for drug discovery.  
 
 
(a) Human CD2                    (b) Rat CD2 
CD58 binding site                 CD48 binding site 
Figure 2-1 The position of residues involved in CD2 ligand binding [28]. (a) Residues of 
human CD2 domain 1 implicated for CD58 binding by site-directed mutagenesis. (b) 
Residues of rat CD2 domain 1 implicated for CD48 binding on the basis of CD48-induced 
chemical shift and differential broadening of cross-peaks in NMR spectrum of rCD2. 
2.1.1 Design of parent peptides from CD2 ligand binding epitopes 
The extracellular regions of the hCD2 and rCD2 share 45% sequence homology. 
Comparison of CD2 sequence has revealed that some loops or turns (such as CC’ and 
C’C” loops) of GFCC’C” β strands are poorly conserved in species (Figure 2-2), 
suggesting the more flexible loops or turns are important for ligand interaction [41]. 
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The ligand-induced conformational change of CD2 and CD58 has revealed that some 
regions (such as C’C” and FG loops/turns) implied for adhesion binding exhibit 
structural plasticity while other regions remain rigid [33]. 
 
 
Figure 2-2 Sequence comparison of hCD2 domain 1 (residue 1-105) and rCD2 domain 1 
(residue 1-99). Structurally equivalent residues are aligned and sequence identities boxed. 
Every tenth residue of each sequence is numbered and glycosylated asparagines are white on 
a black background. Bars represent β-sheets and ﹡marks residues buried in the head-to-head 
interaction observed in human sCD2 crystals [27]. 
 
Mutagenesis and structural studies confirm that the residues in the G, F, C, C’, C” 
β strands as well as the CC’, C’C” and FG loops are implicated in ligand binding of 
rCD2 and hCD2 (red colored residues in Figure 2-3). Most of these residues are 
charged and involved in the electrostatic interactions with ligands [27, 42, 50]. 
Comparison of the rat and human CD2 ligand binding sites suggests that species- and 
ligand-specific binding can be determined by a few residues, such as Thr37, Leu38 
and Glu41 in rCD2 and corresponding Lys42, Lys43 and Gln46 in hCD2 [42]. On the 
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other hand, three residues (Phe49, Tyr81, Gly85 in rCD2 and Phe54, Tyr86, Gly90 in 
hCD2) are conserved in all CD2 homologues and are involved in head-to-head crystal 
contact in CD2 crystals, suggesting that these residues might be directly involved in 
ligand binding [27, 29, 42]. For example, Tyr86 in hCD2 have been identified as hot 
spot in ligand binding [47]. 
 
 
        
(a)                              (b)  
Figure 2-3 Space-filling representation of CD2 ligand binding epitopes. (a) rCD2 binding site 
for CD48 in mutagenesis study. Residues whose substitution significantly interfered with 
CD48 binding are colored red [50]. (b) hCD2 binding site for CD58 in mutational study. 
Residues involved in CD58 binding are high-lighted in red [48]. 
 
In summary, it can be predicted that CD2 ligand binding involves electrostatic 
interactions and hydrogen bonding of interface residues in CC’, CC” and FG loops, 
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2.1.2 Design of parent peptides from CD2 β-turn structure 
Secondary structure analysis has shown that the important loops of CD2 (CC’, 
C’C” and FG loops) are connected by β-turn structures. β turn 
Thr38-Ser39-Asp40-Lys41 (CC’ loop) and Asp87-Thr88-Lys89-Gly90 (FG loop) are 
found in hCD2 (Figure 2-4 (a)), while Arg34-Gly35-Ser36-Thr37 and 
Ser82-Thr83-Asn84-Gly85 serve as the counterparts in rCD2 (Figure 2-4 (b)) [51]. 
These exposed β-turns may serve as binding loci on CD2 surface because many of the 
turn residues or flanking residues are involved in ligand binding (Figure 2-2). For 
example, flanking residue Tyr86 to the β-turn in hCD2 serves as the hot spot in CD2 
ligand binding. In addition, the β-turn on hCD2 C’C” loop 
(Arg48-Lys49-Glu50-Lys51) is also expected to be critical for CD58 binding since the 
turn residue Arg48 and Lys51 participate in four pairs of salt bridge interaction with 
CD58 (Figure 1-4 (b)). 
Furthermore, β-bulges locating immediately after the CC’ and FG turns in rCD2 
(at Leu38 and Arg87) or in hCD2 (Lys43 and Asn92) is an important conserved 
feature in CD2 homologues and plays a significant role in the head-to-head interaction 
in CD2 crystal lattice by forming main-chain hydrogen bonds [27]. These main chain 
H-bonds resulted from the β-bulge conformations allow hCD2 FG loop move closely 
to and interact with hCD58 CC’ loop [45, 47]. Hence, it is not unreasonable to 
anticipate that β-bulges near CC’ and FG turns may also play a critical role in the 
interaction of CD2 with its ligands. 
In conclusion, the critical residues on CD2 CC’, C”C” or FG loops are involved 
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in the formation or stabilization of conserved β-turn and β-bulge structures by 
participating in side chain interaction or main chain hydrogen bonding with ligands. 
Thus, we hypothesize that β-turns connecting CC’, C’C’’ and FG loop may serve as 
binding loci of CD2 with its ligands and cyclic peptides designed from these 
conserved β-turn or β-bulge regions can modulate CD2-CD58 interaction by 
mimicking the native β-turn epitopes.  
 
(a)                                   (b) 
Figure 2-4 β-turn regions in CD2 structure [51]. (a) Ribbon diagram of crystal structure of 
CD2-CD58 complex. The residues of hCD2 that are in β-turn region are shown as red sticks. 
Tyr86 from CD2 is shown in green. Residues from CD58 that are important in the interaction 
of CD2-CD58 are shown in color. Lys32, Glu25 (purple); Asp33, Lys29, Glu37 (blue); Lys30 
(magenta). (b) Crystal structure of rCD2. Residues in the β-turn region are shown as sticks 
and labeled. 
2.1.3 Design of cyclic peptides from CD2 β-turn sequences 
Four parent peptides have been designed based on the important β-turn and 
β-bulge sequences in rCD2 and hCD2 respectively. Some critical residues flanking 
these β-turns were also remained as they may stabilize the β-turns by their side chain 
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interaction. Since small linear peptides do not form stable conformation as the same 
sequence in proteins, these parent peptides were cyclized by Pen-Cys disulfide bonds 
to mimic the β-turn structures of the same sequence in native proteins. 
Of the two peptides designed from rCD2 β-turns, cER contained the β-turn 
sequence (Arg34-Gly35-Ser36-Thr37), the β-bulge residues in C’ strands (Leu38, 
Glu41) as well as the critical flanking residue Glu33. On the other hand, cVL 
contained the β-turn Ser82-Thr83-Asn84-Gly85, the β-bulge residues in G strands 
(Gly85, Arg87) as well as important flanking residues Tyr81 and Thr86 (Table 2-1). 
Similarly, two peptides were designed from the hCD2 β-turns. cAQ contained 
Arg48-Lys49-Glu50-Lys51 β-turn, in which the charged turn residues (Arg48 and 
Lys51) are involved in interaction with CD58. As the counterpart of cVL in hCD2, 
cIL contained the Asp87-Thr88-Lys89-Gly90 β-turn, β-bulge residues in G strands 
(Gly90, Asn92) as well as the critical flanking residue Lys91 and hot spot residue 
Tyr86 (Table 2-1). 
The negative control, linear KGKTDAISVKAI (lKI) was designed by reversing 
of the sequence of hCD2 ‘‘hot spot’’ region [47] and mutation of the Tyr with Ala. 
Table 2-1 Design of 12-aa cyclic peptides from CD2 β-turn structure. The sequence number 
refers to the starting and ending residue number in native CD2. The residues involved in 
native CD2 β-turns are boxed. 
Code Sequence Loop region  Critical residues involved 
cER Cyclo(1,12) PenE33RGSTLVAEF42C rCD2 CC’  E33, L38, E41 
cVL Cyclo(1,12) PenV80YSTNGTRIL89C rCD2 FG Y81, G85, T86, R87 
cAQ Cyclo(1,12) PenA45QFRKEKETF54C hCD2 C’C’’ Q46, R48, K51 
cIL Cyclo(1,12) PenI85YDTKGKNVL94C hCD2 FG Y86, G90, K91, N92 
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2.2 Peptide optimization strategy 
2.2.1 Minimum inhibition sequence (MIS) 
In most cases, within the whole sequence of a protein, functional sites represent a 
very small part of the whole structure and they are hidden within ‘not-reactive’ 
regions that form the protein scaffold. Molecules containing certain amino acid motifs 
are therefore found to be functionally important. The ASC (active sequences 
collection) database, which consists a collection of short amino acid sequences with a 
demonstrated biological activity, is a useful tool to investigate structure-function 
relationships of proteins and peptides as well as design drug candidates with desired 
biological functions [88]. For example, Arg-Gly-Asp (RGD) sequence is an important 
binding site for many integrins, and RGD peptides and mimics can be used to probe 
integrin functions thus provide potential therapeutic agents for some diseases [89, 90].  
In our group’s previous work, cyclic hexapeptides cYT truncated from cVL lost 
majority of the inhibitory activity, while cEL showed even higher activity compared 
to its parent peptide cER [51]. These results made us believe that certain segments are 
required for maintaining the biological activity in the parent peptides. Thus, efforts 
have been made to identify possible minimum inhibition sequences (MIS) in CD2 
derived peptides, which can be further used as lead compounds in designing active 
peptidomimetics.  
To determine the specific segments in parent peptides responsible for inhibitory 
activity as lead sequence, we generated shorter fragments of the parent peptides and 
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evaluated their biological activity. Truncation scanning was carried out by deleting 
one or two residues each time to avoid substantial change of peptide structure (Table 
2-2). Deletion was done away from the core β-turn residues in order to retain the 
β-turn structure in truncated peptides. For example, truncation of cIL and cVL was 
from the C terminal because the hot spot residue (Tyr86 in cIL and Tyr81 in cVL) was 
located near the N terminal. In case of cAQ, the deletion started from both ends as the 
β-turn (Arg-Lys-Glu-Lys) was located in the middle of the sequence. 
2.2.2 Alanine scanning 
For the potent hexapeptide cEL, alanine scanning was performed to investigate 
the roles of certain residues in peptide structure and activity. In contrast to 
hydrophobic residues that are generally buried in the interior of the protein, the 
charged or polar residues exposed on the surface or loop region may participate in 
protein-protein interactions. Therefore, mutagenesis study is often targeted at these 
exposed residues to investigate their contributions to protein-protein interactions. 
Because drastic mutations (such as neutral residues mutated to charged residues or 
charged residues to opposite charged residues) may destroy the peptide structure, 
alanine scanning was used in our study to avoid adverse effect on peptide structure. 
Different types of residues, acidic (Glu), basic (Arg), polar (Ser) and less polar (Thr), 
were individually subjected to alanine mutation to evaluate contribution of different 
side chains to the ligand binding (Table 2-2).  
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Table 2-2 Truncation and alanine scanning of 12-aa cyclic peptides 
Code Sequence 
CER Cyclo(1,12) PenERGSTLVAEFC 
CEL Cyclo(1,6) ERGSTL 
E1A Cyclo(1,6) ARGSTL 
R2A Cyclo(1,6) EAGSTL 
S4A Cyclo(1,6) ERGATL 
L6A Cyclo(1,6) ERGSTA 
CVL Cyclo(1,12) PenVYSTNGTRILC 
CVY Cyclo(1,10) PenVYSTNGTRC 
CAY Cyclo(1,10) PenAYSTNGTRC 
CVR Cyclo(1,8) VYSTNGTR 
CYT Cyclo(1,6) YSTNGT 
CAQ Cyclo(1,12) PenAQFRKEKETFC 
CQT Cyclo(1,10) PenQFRKEKETC 
CFE Cyclo(1,6) FRKEKE 
CIL Cyclo(1,12) PenIYDTKGKNVLC 
CIY Cyclo(1,10) PenIYDTKGKNC 
CIN Cyclo(1,8) IYDTKGKN 
CYK Cyclo(1,6) YDTKGK 
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3.1 Introduction 
Heterotypic adhesion assay based on Jurkat cells and Caco-2 monolayer has been 
established to evaluate the modulation of CD2-derived peptides on CD2-CD58 
interaction in our research group previously [91].  
Since adhesion molecules are widely expressed on various cell types and the 
co-existence of different adhesion pathways may affect the sensitivity and specificity 
of heterotypic cell adhesion assay. To develop a sensitive adhesion assay specifically 
targeting CD2-CD58 interaction, adhesion molecule expression level on different cell 
types (Caco-2 and OVCAR), the effects of cytokine (IFN-γ) and chemokine (PMA) 
on test cells, as well as the adhesion mechanism involved were investigated to 
optimize the experimental conditions. 
3.1.1 Enzyme-linked Immunosorbent Assays (ELISA) 
Enzyme-linked Immunosorbent Assays (ELISA), which combine the specificity 
of antigen-antibody reaction with the sensitivity of enzyme assays, is a widely used 
immunoassay technique for the detection and quantitation of antigens or antibodies in 
vitro. Different types of ELISA are available, such as direct, indirect and sandwich 
ELISA. Each method has its advantages and disadvantages.  
In direct ELISA, only one antibody is used and directly labeled, avoiding 
potential cross-reactivity of the secondary antibody with other components in the 
sample. However, the labeling of every antibody is expensive and certain antibodies 
are unsuitable for direct labeling. Direct ELISA also lacks the additional signal 
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amplification without a secondary antibody [92, 93]. 
The indirect ELISA utilizes an unlabeled primary antibody in conjunction with a 
labeled secondary antibody. Since the labeled secondary antibody is directed against 
all antibodies of a given species (e.g. anti-mouse), it can be used with a wide variety 
of primary antibodies. The use of secondary antibody also provides an additional 
signal amplification, increasing the overall sensitivity of the assay [92, 93]. 
Sandwich ELISA is especially valuable when the concentration of antigens is 
very low (such as hormones, cell signaling chemicals, or cytokines) and/or they are 
contained in high concentrations of contaminating proteins (such as proteins in cell 
culture supernatant or plasma). However, the antigens to be measured must contain at 
least two antigenic sites, capable of binding to antibody, since the antigens are 
measured between two layers of antibodies. So sandwich assays are restricted to the 
quantitation of multivalent antigens such as proteins and polysaccharides [94]. 
3.1.2 Confirmation of antigen expression by cellular imaging 
Fluorescence microscopy is a powerful tool in biological sciences where the 
specific and sensitive fluorescence probes can provide important information 
regarding the biochemical, biophysical and structural status of cells and tissues. For 
instance, immunofluorescence microscopy with tag-specific antibodies can provide 
much data about the location and function of cellular proteins. Laser scanning 
confocal microscopy (LSCM), on the other hand, can identify and localize specific 
cellular components with a submicron axial resolution. LSCM can obtain 
  
Chapter 3. Development of OVCAR-Jurkat cell-cell adhesion assay 
 51 
high-resolution images by rejecting light from out-of-focus planes almost completely, 
and the light from out-of-focus planes is a reason for image deterioration in 
fluorescence microscopy. Moreover, a three dimensional image can be constructed by 
combining a series of sections of the specimen [95]. 
3.1.3 PMA regulation on Jurkat cells 
In previous Caco-2-Jurkat cell adhesion assay, PMA (10 ng/ml) was used to 
pre-treat Jurkat cells for 48h in order to elevate CD2 expression on Jurkat cells. 
However, CD2 level was little up-regulated after PMA treatment [91]. As a 
T-leukemia cell line, Jurkat cells may be sensitive to PMA regulation in cell growth 
and viability that may further affect the adhesive capacity of Jurkat cells. Therefore, 
PMA regulation on Jurkat cells (cell proliferation and cell cycle) was investigated to 
test if PMA treatment is necessary and suitable for further heterotypic adhesion assay. 
3.1.3.1 PMA regulation on cell growth and proliferation 
Protein kinase C (PKC) is a family of isozymes that plays critical role in 
regulating cell growth, proliferation, differentiation and apoptosis, as well as cell 
migration and adhesion. PKC isoforms differ in structure, expression in various cells 
and regulatory properties, thus the biological responses induced by manipulation of 
PKC vary depending on the types and conditions of cells. For example, activation of 
PKC causes growth stimulation in normal melanocytes but growth inhibition in 
malignant melanoma cells. PKC translocates and accumulates on the cell membrane 
upon activation, hence participates in the regulation of cell adhesion or focal contact 
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by interacting with β1-intergrin or other proteins [96, 97]. 
PMA is a well-known non-specific PKC activator that activates many PKC 
members (such as α, β, γ) resulting in isoform down-regulation. Since the 
susceptibility and rate of down-regulation of certain isoforms upon long-term PMA 
treatment may vary in different cells, PMA exerts mitogenic or antiproliferative effect 
in different cell systems [96, 97]. For example, PMA/ionomycin combination is 
widely used to activate human thymocytes or peripheral blood lymphocytes (PBL) 
and induce cell proliferation in vitro [98]. In contrast, low concentration of PMA (0.5 
ng/ml) was found to induce growth inhibition in a human B lymphoblastic cell line 
(HT58) by arresting cells in G1 phase [96].  
3.1.3.2 Cell cycle analysis by flow cytometry 
Under proper stimulation, quiescent cells which is in the resting state (G0) can 
enter the mitotic cycle comprising four different stages: G1, S, G2, and M. The cells 
first enters the gap (G1) phase of the cell cycle during which there is an increase in 
both RNA and protein synthesis. When the cells start to make new DNA they transit 
into DNA synthetic (S) phase of the cell cycle. During this phase, the DNA content of 
the cells increase until they have doubled, after which the cells enter the second gap 
(G2) phase. Finally the cells enter the mitosis (M) phase and divide, after which the 
cells either join the resting cells (G0) or begin a new mitotic cycle by re-entering G1 
phase [99, 100]. 
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Due to the finding that the cellular DNA content in G2/M phases is double that 
of G0/G1 phases, while cells in the S-phase have a DNA content lying between the 
extreme of G0/G1 and G2/M phases, therefore quantitative fluorescent staining and 
flow cytometric (FCM) analysis of cellular DNA content has been one of the most 
rapid and reliable approaches for obtaining cell cycle frequency distributions of cell 
populations [99]. Cells are stained with dyes that can intercalate with DNA before 
analyzed using FCM, in which fluorescent stained cells are transported in a liquid 
medium one by one and at meantime the dye is excited by intense light. The resulting 
fluorescence is proportional to the amount of DNA to which the dye is bound (Figure 
3-1). 
Propidium iodide (PI) is one of the red fluorochromes commonly used for 
DNA-staining. Since PI can intercalate into base pairs of double-stranded DNA and 
RNA without base specificity, it is necessary to pre-treat the fixed cells with RNase 










Figure 3-1 DNA histogram in flow cytometric analysis 
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3.1.4 Mechanism of OVCAR-Jurkat heterotypic cell adhesion  
Adhesion molecules CD2 and LFA-1 mediate distinct adhesion pathways 
complementary for T cell activation. On one hand, LFA-1 mediated adhesion is 
minimal in non-activated T cells but is augmented within minutes following 
TCR-mediated activation. In contrast, CD2 function is essentially optimal in 
non-activated T cells and undergoes no detectable modification under TCR 
stimulation. The TCR independence of CD2 adhesion function implies a critical role 
of the CD2 pathway in initiating cell-cell interactions prior to T cell triggering and 
LFA-1/ICAM-1 binding [101]. Upon activated by T cell triggering, LFA-1 adhesion 
pathway will strengthen the CD2 adhesion by further contributing to the interaction 
forces although at a distance from optimal CD2-CD58 contact area. Such reinforced 
cell contact may be critical for generation of stable junction required for efficient CTL 
lysis of target cells [45]. Studies by Tibaldi et al also confirmed the complementary 
roles of CD2 and LFA-1 in T cell scanning of APCs [54]. 
CD2 and LFA-1 mediated cell adhesion differ in many ways. Firstly, unlike 
CD2/CD58 adhesion, LFA-1/ICAM-1 binding is dependent on temperature and 
divalent cations (Mg2+ or Mn2+) [102]. Secondly, activation of PKC by some stimuli 
(such as PMA) augments LFA-1 but not CD2 adhesion pathway. This function of 
PKC can be explained by the translocation of PKC on cell membrane involved in cell 
adhesion, as well as the interaction of PKC with LFA-1 by enhancing the affinity of 
LFA-1 for ligands [97, 101]. 
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3.2 Materials and methods 
3.2.1 Materials  
Mouse anti-human CD58 (LFA-3) monoclonal antibody (clone TS2/9) and 
mouse anti-human CD54 (ICAM-1) domain D1 monoclonal antibody (Clone 15.2) 
were purchased from Ancell Corporation (Bayport, MN, USA). FITC-conjugated 
mouse anti-human CD58 (clone 1C3) was purchased from BD Biosciences (San 
Diego, CA, USA). Mouse anti-human CD2 monoclonal antibody (clone M504501) 
was from Fitzgerald Industries International Inc. (Concord, MA, USA), and 
FITC-CD2 conjugated antibody (clone 39C1.5) was obtained from Immunotech 
(Marseille, France). Goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate 
and ABTS in a GEM ELISA Kit were purchased from QED Bioscience Inc. (San 
Diego, CA, USA). 
Triton X-100 and EDTA were purchased from Bio-Rad Laboratories (Hercules, 
CA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was 
provided by Duchefa Biochemie (Haarlem, Netherlands), and dimethyl sulfoxide 
(DMSO) was a product from Mallinckrodt Baker Inc., (Phillipsburg, NJ, USA). 
Absolute alcohol (A.R quality) was a product of Hayman Limited (Witham, Essex, 
England). 
Bovine serum albumin (BSA) and human recombinant IFN-γ were purchased 
from Sigma-Aldrich Inc., (St. Louis, MO, USA). Paraformaldehyde (PFA), propium 
iodide (PI), Ribonuclease A (RNase), Phorbol ester, 12-myristate-13-acetate (PMA), 
trypan blue, sodium bicarbonate and penicillin G sodium salt were obtained from 
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Sigma-Aldrich CO. (St. Louis, MO, USA). N-[2-Hydroxyethyl] 
piperazine-N’-[2-ethanesulfonic acid] (HEPES), sodium dodecyl sulfate (SDS), 
Trypsin-EDTA solution and streptomycin sulfate were provided by Sigma Chemical 
CO. (St. Louis, MO, USA). 
Minimum essential medium alpha medium (MEM-α), MEM non-essential amino 
acids (NEAA) solution and RPMI 1640 medium were purchased from Gibco 
Invitrogen Corporation (Grand Island, NY, USA). Fetal bovine serum (FBS) was 
provided by Hyclone Laboratories Inc., (Logan, UT, USA). 10×PBS (phosphate 
buffered saline) was purchased from the laboratory supplies store in National 
University Medical Institutes, NUS. Deionized water prepared form Millipore system 
(Bedford, Massachusetts, USA) was used throughout. 
3.2.2 Cell lines and cell culture 
The human colon carcinoma-epithelial (Caco-2) cell line and the T-leukemia 
cells Jurkat (Clone E6-1) were obtained from the American Type Culture Collection 
(Rockville, MD). The OVCAR cells were kindly provided by Associate Professor Ho 
Chi Lui, Paul’s group from Department of Pharmacy, National University of 
Singapore. Cells were grown in 75cm2 tissue culture flasks (NunclonTM, Roskilde, 
Denmark) in a Forma direct heat CO2 incubator (Thermo Electron Corporation, 
Beverly, MA, USA) at 37℃ with 5% CO2. 
Caco-2 cells were maintained in MEM-α containing 10% FBS, 1% NEAA, and 
100 mg/L of penicillin G/streptomycin sulfate. The medium was changed every other 
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day until the cells reached 80-90% confluence observed under an OLYMPUS CK2 
microscope (Olympus Corporation, Tokyo, Japan). Subculture was carried out at a 
split ratio of 1:3 by treating with Trypsin-EDTA for 5-10 minutes at 37℃. Caco-2 
cells were used between passages 50 and 60. 
OVCAR cells were maintained in RPMI 1640 medium supplemented with 10% 
FBS and 100 mg/L of penicillin G/streptomycin sulfate. The medium was changed 
every other day until the cells reached 80-90% confluency. Subculture was carried out 
at a split ratio of 1:3 by treating with trypsin-EDTA for 3-5 minutes at 37℃. Cells 
with the passage number of 40-50 were used for the adhesion assay for consistency. 
Jurkat cells were maintained in suspension in RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS and 100 mg/L of penicillin G/streptomycin sulfate. 
Subculture was carried out by centrifuging with a Jouan BR4i centrifuge (Thermo 
Electron Corporation, Beverly, MA, USA) at 1000 rpm for 3min and replacing with 
fresh medium. 
3.2.3 Antigen expression by ELISA assay 
ICAM-1 (CD54) and LFA-3 (CD58) are respectively involved in LFA-1 
mediated and CD2-mediated cell adhesions. Both antigens are widely expressed on a 
variety of melanoma cell lines, including leukocytes, endothelium, epithelium and 
fibroblasts. The antigen expression varies with cell lines and can be upregulated by 
some cytokines, such as TNF-α and IFN-γ [103, 104]. To ascertain the presence of 
these adhesion molecules and their response to cytokines, the expression of CD54 and 
  
Chapter 3. Development of OVCAR-Jurkat cell-cell adhesion assay 
 58 
CD58 on untreated or IFN-γ-treated epithelial cell monolayers (Caco-2 and OVCAR) 
were investigated using an indirect ELISA.  
Caco-2 and OVCAR cells were seeded at a density of 104 cells/well in 96-well 
tissue culture plates (NunclonTM, Denmark) and incubated at 37 ℃ with 5% CO2 
overnight to allow cells adhere to the bottom. Fresh media with IFN-γ (1000 U/ml) 
was changed at indicated time and incubated for a total time of 72h to nearly 
confluence. The time of cell monolayer exposure to IFN-γ was 72, 48 and 24h 
respectively. Fresh media without IFN-γ was used in untreated control. 
The antigen expression was tested by a reported ELISA assay with minor 
modification [91]. Cells were rinsed twice with PBS and fixed with 3% PFA/PBS for 
15 min at RT. Cells were then washed and blocked with 1% BSA/PBS for 1h, and 
incubated with primary antibodies (anti-CD54 mAb or anti-CD58 mAb)(1:500) at 4℃ 
overnight. The cells were washed three times with 1%BSA/PBS before incubating 
with secondary antibody anti-mouse IgG–HRP conjugate (1:1000) for 2h. The cells 
were washed five times with 1%BSA/PBS, and incubated with substrate solution 
(ABTS) for 40 min at room temperature before adding 1% SDS to stop the reaction. 
Optical density (O.D.) readings were taken at 430 nm. 
3.2.4 Antigen expression by cellular imaging 
CD2 expression on Jurkat cells was confirmed by fluorescence microscopy. 
Jurkat cells were washed with 1% BSA/PBS and 1×106 cells were incubated with 
20µl of FITC-CD2 mAb in the dark at 4℃ overnight. Cells incubated in the absence 
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of mAb were used as the negative control. The cells were washed with 1% BSA/PBS 
by centrifuging at 2000 rpm for 5min, then fixed with 1% PFA/PBS for 10min. Fixed 
cells were washed with 1% BSA/PBS and stored in the dark at 4 ℃ before observed 
under a fluorescence microscopy (Nikon Eclipse TE2000-U, Nikon Instech Co., Ltd. 
Kawasaki, Kanagawa, Japan) at 20×magnitude. 
CD58 expression on OVCAR cells was confirmed by LSCM. OVCAR cells 
were cultured in 75cm2 flask (NunclonTM, Denmark) until nearly complete confluence. 
Cells were detached using 10mM EDTA in 2%HEPES/PBS for 8-10 min at 37℃. The 
cells were washed with 1%BSA/PBS and 1×106 cells were incubated with 20µl 
FITC-CD58 mAb or 1% BSA/PBS (negative control) at 37℃ for 1h in the dark. 
After washing with 1%BSA/PBS, the cells were fixed with cold 0.5%PFA/PBS and 
plated on glass cover slips. Then the cover slips were mounted on microscope slides 
before observed under an inverted laser scanning confocal microscopy (Zeiss 
Axiovert 200M, Oberkochen, Germany) with an imaging software (LSM 5 Image 
Browser, Carl Zeiss, Oberkochen, Germany). 
3.2.5 PMA regulation on Jurkat cells  
3.2.5.1 PMA effect on Jurkat cell proliferation  
Jurkat cell proliferation upon PMA treatment was investigated with MTT assay 
indicated in 4.2.5.1. In brief, Jurkat cells in logarithm phase were adjusted to 5×105 
cells/ml and seeded in 96-well plates (NunclonTM, Denmark) at 100 µl/well. 100 µl of 
PMA prepared in media was added to the wells to a final concentration of 10 ng/ml 
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while media alone as control. The plates were incubated at 37℃ for indicated time 
before 20 µl of MTT solution (5mg/ml in PBS) was added to each well and incubated 
at 37℃ for another 4h. The plate was centrifuged at 1500 rpm for 5min and the 
supernatant was carefully aspirated before 100 µl of DMSO was added to each well. 
The absorbance was measured at 590 nm using a plate reader (Spectra Fluor, Tecan 
Group Ltd., Mannedorf, Switzerland). The proliferation index under PMA treatment 
was expressed as the percentage of viable cells in samples compared with that in 
respective controls at indicated time points. 
3.2.5.2 PMA effect on Jurkat cell cycle  
Jurkat cells grown in logarithm phase were adjusted to 2.5×105/ml and seeded in 
12-well plates at 4ml/well to ensure enough cells for cell cycle analysis. After treated 
with PMA (10 ng/ml) for indicated time, Jurkat cells were harvested and washed 
twice with PBS at 2000 rpm for 5min. The cell pellet was then resuspended in 1ml 
PBS to make a 1×106 cells/ml suspension and 3ml cold absolute ethanol was added to 
fix cells more than 2hr at －20℃. Cells may be stored in 70 % ethanol at －20℃ 
for several weeks prior to PI staining and cell cycle analysis. The cells were washed 
twice with PBS at 2000 rpm for 6min before stained in 1ml freshly prepared PI 
staining solution (To 10 ml of 0.1% (v/v) Triton X-100 in PBS, add 2 mg DNase-free 
Rnase A and 200 µl of 1mg/ml PI stock solution). 
Determination of the cell cycle of the PI-stained cells was performed with a flow 
cytometer (AltraTM, Beck-coulter Inc., Germany). 10,000 nuclei were counted for 
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each sample and cell cycle analysis was performed using winMDIv 2.8 software. The 
cell cycle distribution was expressed as the percentage of M1 (sub-G1 phase), M2 
(G0/G1 phase), M3 (S phase) and M4 (G2/M phase). The S and G2/M phases were 
combined to determine the proliferation index (PI).  
PI (%)=(S+G2/M)/(G0/G1+S+G2/M)×100 
3.2.6 Adhesion mechanism in OVCAR-Jurkat cell adhesion 
The effects of temperature, PMA and antibodies on OVCAR-Jurkat heterotypic 
adhesion were investigated to elucidate the possible mechanisms.  
3.2.6.1 Temperature and PMA effects 
Adhesion assays were carried out at different temperature (37℃ or 4℃) to 
investigate the temperature effect because temperature dependence is one major 
difference between CD2/CD58 and LFA-1/ICAM-1 adhesion pathway.  
CD2 and LFA-1 mediated cell adhesion responses differently to PMA regulation, 
thus the cell adhesion assay was also performed in the absence or presence of PMA. 
3.2.6.2 Antibody effect 
To confirm the mechanism(s) involved in OVCAR-Jurkat heterotypic cell 
adhesion assay, antibodies to different adhesion molecules (CD54, CD58 and CD2) 
were used to investigate their contribution to the heterotypic cell adhesion. OVCAR 
cells were pre-treated with CD54 or CD58 mAb, while Jurkat cells were pre-treated 
with CD2 mAb for 30 min at 37℃ before performing the adhesion assay. If certain 
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antibody inhibits the cell adhesion, the corresponding adhesion molecule may be 
involved in the adhesion mechanism. 
3.3 Results and discussion 
3.3.1 CD54 and CD58 expression by ELISA assay 
CD2 and LFA-1 mediate distinct cell adhesion by binding to their respective 
ligands, CD58 and CD54. Ligand expression level is important for the binding affinity 
between adhesion molecules and their counter receptors. Thus, we investigated the 
expression of CD54 and CD58 on OVCAR and Caco-2 cell lines. In untreated cells, 
OVCAR expressed higher level of CD58 (about 33% higher) than Caco-2, while 
Caco-2 expressed more than double of CD54 than OVCAR (Figure 3-2).  
The effect of IFN-γ on the expression of CD54 and CD58 was also studied. In 
Caco-2 cells, a slight decrease (～10%) was found on CD58 expression. However, 
little change was found on CD54 expression after exposure to IFN-γ, which might be 
due to CD54 was already maximally expressed on Caco-2. In OVCAR, although 
IFN-γ effect on CD58 expression was similar to that in Caco-2 (slight decrease), 
CD54 expression was upregulated after IFN-γ treatment with a significant increase of 
49% after 24h and 34% after 48h respectively (Figure 3-2).  
The ELISA results indicated CD54 and CD58 were co-expressed on the cell lines 
investigated (Caco-2 and OVCAR), and CD54 was more sensitive to IFN-γ regulation 
than CD58, especially in OVCAR cell line. These findings suggested that CD2/CD58 
and LFA-1/ICAM-1 adhesion pathways co-existed in heterotypic cell-cell adhesion, 
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and CD2/CD58 instead of LFA-1/ICAM-1 pathway was resistant to IFN-γ modulation, 
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Figure 3-2 CD54 and CD58 expression on (a) OVCAR and (b) Caco-2 cells. Mean±SD 
(n=6) 
The aim of our study is to investigate the modulation of CD2-derived peptides on 
CD2/CD58 interaction, thus adhesion mediated by LFA-1/ICAM-1 (CD54) should be 
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minimized to enhance specificity of the heterotypic cell-cell adhesion assay. Therefore, 
OVCAR cells expressing higher CD58 and lower CD54 than Caco-2 cells were used 
to establish the heterotypic cell adhesion assay. Since CD54 expression instead of 
CD58 was up-regulated after IFN-γ treatment, we did not pre-treat OVCAR cell 
monolayer in the adhesion assay. 
3.3.2 Confirmation of CD2 and CD58 expression 
Constitutive expression of CD2 on Jurkat cells was confirmed by fluorescence 
microscopy (Figure 3-3(a)), while CD58 expression on OVCAR cells was confirmed 
by confocal microscopy with a high-resolution image (Figure 3-3(b)). The confocal 
microscopy image indicated that OVCAR cells expressed membrane-bound CD58. 
The interaction between the membrane-bound CD58 and CD2 antigens was 














Figure 3-3 Confirmation of antigen expression. (a) Fluorescent microscopy of Jurkat cell 
suspensions immunolabeled with FITC-CD2 mAb. (b) Confocal micrography of OVCAR cell 
suspensions immunolabeled with FITC-CD58 mAb. 
(b) 
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3.3.3 PMA effects on Jurkat cells 
3.3.3.1 PMA effect on Jurkat cell growth  
The MTT assay results indicated that Jurkat cell growth was inhibited by PMA 
treatment and the inhibition effect was time-dependent. The growth inhibition was 
significant after long-term incubation, with a decreased growth rate of 68% and 53% 




















Figure 3-4 PMA effect on Jurkat cell growth in MTT assay. Mean±SD (n=6) 
3.3.3.2 PMA effect on Jurkat cell cycle 
Long-term PMA treatment resulted in Jurkat cell growth inhibition in MTT assay, 
while Jurkat cell viability was not significantly affected in trypan blue exclusion test 
(data not shown), suggesting the antiproliferative effect may result from PMA 
modulation of Jurkat cell cycle. Thus, the possible mechanism of PMA 
antiproliferative effect on Jurkat cells was investigated by cell cycle analysis. 
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Figure 3-5 DNA content histograms of untreated Jurkat cells (left) and PMA-treated Jurkat 
cells (right) at different incubation time. M1: sub-G1 phase; M2:G0/G1 phase; M3: S phase; 
M4: G2/M phase. 
3.3.3.2.1 PMA induced G1 phase arrest 
The DNA content histograms of untreated or PMA-treated Jurkat cells (Figure 
3-5) were used to analyze cell distribution in different cell cycle phases. Jurkat cell 
cycle arrest was observable in the G1 phase after long-term (24h and 48h) PMA 
treatment. As shown in Table 3-1, the G1 block was detectable after 12hr incubation 
with PMA, with 60.2% cells in G1 phase compared to 55.8% of the control cells in 
G1 phase. The G1 phase arrest was more pronounce after long-term treatment, with 
70.4% (24hr) and 75.4% (48h) cells in G1 phase respectively, while no significant 
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change in G1 phase percentage was found in the controls. The cell cycle distribution 
results suggested that G1 phase arrest was a reasonable explanation for PMA 
inhibition on Jurkat cell growth. Since the cells blocked in G1 phase did not enter next 
cell cycle phases or divide into new cells, the total viable cells in PMA-treated 
samples decreased compared to the untreated controls, as observed in MTT assay. 
Table 3-1 Cell cycle distribution in Jurkat cells. ﹡PI= (S+G2/M)/(G0/G1+S+G2/M)×100 
Cell Cycle distribution (%) Treatment 
Sub-G1 G0/G1 S G2/M 
PI (%) 
Control 2.38 54.70 18.04 24.93 44.00 0h 
PMA 2.38 54.70 18.04 24.93 44.00 
Control 2.15 47.90 19.27 30.61 51.01 4h 
PMA 1.37 46.07 22.27 31.48 53.85 
Control 1.81 51.80 16.95 29.44 47.24 8h 
PMA 1.71 51.40 15.81 31.41 47.88 
Control 1.73 55.82 15.82 26.68 43.23 12h 
PMA 2.24 60.19 10.31 27.51 38.59 
Control 2.13 55.58 23.36 19.04 43.27 24h 
PMA 8.62 70.42 7.10 13.91 22.98 
Control 1.28 57.44 19.35 22.01 41.86 48h 
PMA 8.74 75.38 6.85 9.21 17.56 
3.3.3.2.2 PMA induced proliferation inhibition 
It has been known that PMA exerts either mitogenic or antiproliferative effect in 
different cell systems [96, 97]. Our cell cycle analysis results revealed that PMA 
induced antiproliferative effect on Jurkat cells. As shown in Figure 3-6, the 
proliferation curves of the control and PMA-treated sample were very similar before 
12h with the highest proliferation rate at 4h. However, after 12h, the proliferation rate 
of PMA-treated sample was much lower than the control with PI of 22.98% (24h) and 
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17.56% (48h) respectively. The proliferation curve suggested the cell proliferation 
inhibition after long-term PMA-treatment (>12h), which was in accordance with the 
result of MTT assay. 
 
  
Figure 3-6 Proliferation curve of Jurkat cells in cell cycle analysis 
3.3.3.2.3 PMA induced cell death 
The sub-G1 phase in the flow cytometric DNA content histogram represents 
dead cells in the cell population. The modes of cell death include apoptosis, necrosis 
as well as mitotic or delayed reproductive death. The mitotic or delayed reproductive 
death occurs as a result of exposure to relatively low doses of drugs or radiation, 
which induce irreparable damage, but allow cells to complete at least one round of 
cell division. Because these dying cells show some features of apoptosis, the mitotic 
or delayed reproductive death is thought of as delayed apoptosis or atypical apoptosis 
[99]. As PMA can exert mitogenic effect on cells, mitotic or delayed reproductive 
death is a most possible reason for PMA-induced Jurkat cell death. 
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The dead Jurkat cells were increased after long-term PMA treatment (>12h), but 
the percentage was no more than 10% (Table 3-1), indicating the viability of cells was 
not significantly damaged during long-term PMA treatment. The conclusion was 
supported by trypan blue exclusion test in which cell viability of PMA-treated 
samples was always higher than 85%. Therefore, PMA-induce cell death was not a 
major reason for the anti-proliferative effect of PMA.  
In summary, MTT assay and cell cycle analysis indicated that long-term PMA 
treatment (>12h) caused growth and proliferation inhibition on Jurkat cells, and the 
antiproliferative effect was mainly due to the G1 phase arrest instead of the 
PMA-induced mitotic cell death. 
3.3.4 Mechanisms of OVCAR-Jurkat cell-cell adhesion 
3.3.4.1 Temperature and PMA effects on cell adhesion 
The temperature and PMA effects on cell adhesion were shown in Figure 3-7. 
The finding that cell adhesion was effective at both 37℃ and 4℃ in the absence of 
PMA suggested that CD2 adhesion pathway was widely involved in OVCAR-Jurkat 
heterotypic adhesion, because CD2 mediated adhesion is independent on temperature 
and PMA treatment. On the other hand, cell adhesion enhanced by PMA was 
significant at 37℃ but not found at 4℃, indicating that PMA induction effect was via 
LFA-1 pathway since CD2 adhesion is temperature insensitive.  
Results from temperature and PMA experiments indicated that CD2 adhesion 
pathway participated in OVCAR-Jurkat heterotypic cell adhesion at various 
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temperatures. Although PMA enhanced the heterotypic cell adhesion, it introduced or 
induced another adhesion pathway of LFA-1/ICAM-1, which may deteriorate the 
specificity of the method. To specifically investigate CD2-CD58 interaction, 
OVCAR-Jurkat cell adhesion assay was conducted in the absence of PMA, ensuring 
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Figure 3-7 PMA effects on OVCAR-Jurkat cell adhesion at (a) 37℃ (b) 4℃. Mean±SD 
(n=6) 
  
Chapter 3. Development of OVCAR-Jurkat cell-cell adhesion assay 
 72 
3.3.4.2 Antibody effect on cell adhesion 
As shown in Figure 3-8, all the three tested antibodies (CD2, CD58 and CD54 
mAbs) inhibited heterotypic adhesion in a concentration-dependent manner. At 1:500 
dilution ratio (2µg/ml), a more significant inhibition was found on pretreatment with 
CD58 mAb (48%) than with CD54 mAb (33%), suggesting a more significant role of 
CD58 than CD54 in OVCAR-Jurkat cell adhesion. Significant inhibition was also 
observed in the presence of CD2 mAb (64%), indicating the important role of CD2 in 
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Figure 3-8 Antibody effect on OVCAR-Jurkat cell adhesion. Mean±SD (n=6) 
The antibody inhibition studies suggested that both CD2 and LFA-1 adhesion 
pathways were involved in OVCAR-Jurkat heterotypic cell adhesion whereas CD2 
pathway played a more significant role than LFA-1 pathway. Therefore, the major 
mechanism of OVCAR-Jurkat heterotypic adhesion was through CD2-CD58 
interaction. 
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3.4 Conclusion 
We have successfully developed the OVCAR-Jurkat adhesion assay on the basis 
of a previously reported heterotypic adhesion method. ELISA results indicated that 
the replacement of Caco-2 with OVCAR cell line was reasonable. The sensitivity was 
enhanced because OVCAR cells expressed higher level of CD58 than Caco-2 cells, 
while the specificity could also be increased as lower level of CD54 on OVCAR 
would minimize the contribution of LFA-1/ICAM-1 mediated adhesion.  
Unlike the previous method, PMA was no longer used in OVCAR-Jurkat 
adhesion assay due to the following reasons. Firstly, long-term PMA pretreatment of 
Jurkat cells little up-regulated CD2 expression [91], but greatly inhibited Jurkat cell 
growth and proliferation as shown in the MTT assay and cell cycle analysis. The cell 
cycle analysis further suggested that PMA inhibition was via G1 phase arrest. 
Secondly, PMA significantly induced LFA-1 mediated adhesion which would impose 
adverse effect on the specificity of the method. 
The adhesion mechanism of OVCAR-Jurkat adhesion assay was investigated and 
confirmed. Our study suggested that, under the modified conditions, CD2 pathway 
played a more significant role than LFA-1 pathway although both mechanisms were 
involved.  
Taken together, the modified OVCAR-Jurkat heterotypic cell adhesion assay by 
replacing Caco-2 cells with OVCAR cells as well as conducting adhesion assay 
without PMA pretreatment, was a sensitive and specific method presumably suitable 
for investigating CD2-CD58 interaction. 
  













BIOLOGICAL ACTIVITY OF CD2-DERIVED PEPTIDES 
  
Chapter 4. Biological activity of CD2-derived peptides 
 75 
4.1 Introduction 
Four series of peptides (cER, cVL, cAQ and cIL series) were designed from 
rCD2 and hCD2 to modulate CD2-CD58 interaction. Biological activities of these 
peptides were firstly investigated by OVCAR-Jurkat cell adhesion assay and E-rosette 
inhibition assay. Cell viability assays were then carried out to access the potential 
toxicity of the peptides. Finally, Jurkat-immobilized ICAM-1 adhesion assay was 
carried out to confirm the selectivity of the peptides to inhibit adhesion between 
CD2-CD58 interaction among several pairs of adhesion molecules. 
4.1.1 Solid phase peptide synthesis (SPPS) 
    The solid phase peptide synthesis (SPPS) is a rapid, high-yielding and 
automatic method for synthesis of long chain peptides in solution. In SPPS, all the 
amino acids are protected by Boc/benzyl or Fmoc/tert-butyl, with the α-amino group 
protected by Boc or Fmoc, while the side chain functionality protected by benzyl or 
tert-butyl groups. The first protected amino acid is attached to an insoluble 
polystyrene solid support (resin). After deprotecting the Boc or Fmoc protecting group 
by TFA or piperidine, the next protected amino acid couples to the amino peptide 
resin in the presence of activator (such as HATU). The deprotection and coupling 
steps are repeated until the desired sequence of the peptide is assembled. The final 
peptide is cleaved and deprotected from the resin simultaneously, purified and 
characterized [105].  
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In classical Boc-based SPPS, peptide-resin is treated with anhydrous hydrogen 
fluoride (HF) to cleave the benzyl ester linking the peptide to the resin as well as the 
benzyl protecting group, which requires a special apparatus for safe handling. On the 
other hand, Fmoc-based SPPS provides an alternative to the Boc SPPS and offers the 
advantage of a milder acid cleavage process. In Fmoc SPPS, the acid-liable ether resin 
is used and final cleavage of the peptide can be carried out by treatment with 
TFA/DCM [105].  
4.1.2 OVCAR-Jurkat cell-cell adhesion assay 
To enhance sensitivity and specificity, the OVCAR-Jurkat cell adhesion assay 
has been developed on the basis of previous heterotypic adhesion assay to evaluate the 
biological activity of CD2-derived peptides. On one hand, based on ELISA results of 
surface adhesion molecules (CD54 and CD58), OVCAR cells were used to replace 
Caco-2 to reduce the contribution of LFA-1/ICAM-1 interaction to the heterotypic cell 
adhesion. On the other hand, PMA treatment of Jurkat cells was no longer used in this 
assay dependent on our further investigation of PMA effects on cell growth and cell 
adhesion.  
4.1.3 E-rosetting assay 
Binding of human T lymphocytes to sheep (E)rythrocytes is an antigen 
independent adhesion termed “E-rosetting”. Until the introduction of monoclonal 
antibodies, E-rosetting has long been the main tool for identification and purification 
of human T cells. Like sheep erythrocytes, human erythrocytes can rosette with 
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thymocytes, activated T lymphocytes and some T cell tumors [106]. Human T cells 
rosette with human or sheep erythrocytes through the interaction of CD2 antigen with 
LFA-3 on human erythrocytes or T11 target structure (T11TS) on sheep erythrocytes. 
It was found that hCD2 bound to sheep T11TS and human LFA-3 in a highly specific 
fashion and with similar affinity, which was most likely due to a structural homology 
of these two molecules [106, 107].  
Since LFA-3 and T11TS are structural and functional homologues in human and 
sheep, E-roseeting assay with human T cells and sheep red blood cells (SBRC) can be 
a good evidence of CD2-CD58 interaction. Therefore, E-rosetting inhibition assay 
was used in our study to investigate the activities of designed peptides to block 
CD2-CD58 interaction. 
E-rosetting technique has the drawback of being extremely sensitive to 
methodological variation and treatment of SRBC with urea derivative AET is one of 
the effective ways to stabilize E-rosettes. With AET treatment, E-rosette formation 
becomes less dependent on experimental conditions. The number of SRBC attached to 
each rosette-forming lymphocyte (RFC) is markedly increased thus lead to a sharper 
distinction between and RFC and non-RFC. At the same time, the stability of rosettes 
is greatly enhanced [108]. 
4.1.4 Cytotoxicity assay 
Cytotoxicity assays are widely used to measure changes in cell viability in a 
sample. It can be used to optimize the cell culture condition, and more importantly to 
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access the potential cytotoxicity of some therapeutical agents. Many cytotoxicity 
assays are based on metabolic activity or cell membrane integrity of viable cells. 
Metabolic impairment assays measure the decay of enzyme activity or metabolite 
concentration following toxic insult by incubating with a tetrazolium salt (e.g. MTT, 
XTT, WST-1). MTT assay is an in vitro cell viability assay widely used to examine 
cell proliferation, cytotoxicity and apoptosis. The yellow-colored tetrazolium, MTT, 
can be reduced by metabolically active cells to generate purple formazan that can be 
solubilized and quantified by spectrophotometric means [99]. 
The membrane integrity assays measure the ability of cells to exclude 
impermeant extracellular molecules, which can be either colorimetric (such as trypan 
blue) or fluorescent (such as FDA). Viable cells with intact plasma membranes can 
accumulate neutral and non-fluorescent FDA intracellularly and hydrolyse it to 
fluorescein, which is anionic and highly fluorescent. On the other hand, dead cells 
lack the ability to accumulate and hydrolyse FDA, and are therefore non-fluorescent. 
The generated fluorescence is linearly proportional to the number of viable cells under 
a variety of conditions [99]. 
4.1.5 Jurkat cell-immobilized ICAM-1 adhesion 
Due to the fact that β2 intergrins are exclusively expressed by leukocytes, 
interaction between LFA-1 and its ligands (the principal ligand of ICAM-1) is another 
important cell adhesion mechanism, in addition to CD2/CD58, which is involved in 
the recruitment of leukocytes to sites of inflammation, stabilizing the interaction 
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between T cells and APCs, as well as providing co-stimulatory signals. 
LFA-1 has a two-way signaling function, “inside-out” and “outside-in” 
respectively, mediating cell adhesion and stimulating intracellular process at the same 
time. The “inside-out” signaling, which can be achieved by TCR/CD3 complex, other 
leukocyte surface receptors as well as tumor-promoting agent PMA, causes transient 
activation of LFA-1 from inactive to active ligand-binding status. On the other hand, 
the “outside-in” signaling that can be triggered via crosslinking of LFA-1 to outside 
stimuli (e.g. ICAM-1), can affect cellular functions such as apoptosis, proliferation, 
cytokine production and antigen presentation. Molecules implicated in 
LFA-1-mediated signaling include protein tyrosine kinase (PTK), PKC, intracellular 
calcium levels [109]. 
Complemetarity of these two distinct adhesion pathways was confirmed by the 
finding that co-expression of CD58 and CD48 with ICAM-1 on target cells resulted in 
strong adhesion of resting NK cells and thus CD2 mediated adhesion strengthen the 
LFA-1 mediated adhesion on resting NK cells [110]. In an in vitro allograft rejection 
model of IFN-γ–treated endothelial cells, a distinct inhibition of T cell proliferation 
was observed with mAbs against LFA-1 and CD2, suggesting that CD2/CD58 and 
LFA-1/ICAM-1 interactions were both involved in allogenic rejection [111]. 
LFA-1 and CD2-mediated adhesion may co-exist in our developed hyterotypic 
cell adhesion models because of the fact that LFA-1 and CD2 are widely expressed in 
leukocytes (such as Jurkat cells). Furthermore, co-expression of their respective 
ligands, CD54 and CD58, were confirmed in both Caco-2 and OVCAR cells in 
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ELISA study. Although OVCAR cells with low ICAM-1 (CD54) expression were 
used in the heterotypic cell-cell adhesion assay to minimize ICAM-1/LFA-1 adhesion 
pathway, the ICAM-1/LFA-1 mediated cell adhesion could not be excluded 
completely in the heterotypic adhesion assay. To ascertain the mechanism of our 
peptides’ inhibitory activity, we tested the peptide activity using the Jurkat 
cell-immobilized ICAM-1 adhesion assay, in which the cell adhesion was merely 
mediated by LFA-1/ICAM-1 interaction between Jurkat cells and plate coated 
ICAM-1. 
4.2 Materials and methods 
4.2.1 Materials 
4.2.1.1 Reagents 
The PAL amide resin was purchased from Advanced ChemTech (Louisville, KY, 
USA) and the Nα-Fmoc derivatives of standard amino acids were purchased from 
NovaBiochem (San Diego, CA, USA). Diisopropylethylamine (DIEPA) and 
piperidine were purchased from Applied Biosystems (Foster City, CA, USA). 
Trifluoroacetic acid (TFA), thioanisole and ethandithiol (EDT) were provided by 
Sigma-Aldrich Inc. (St. Louis, MO, USA). N, N’-Dimethylformamide (DMF), 
dichloromethane (DCM), ether and acetonitrile (ACN) were purchased from Fisher 
Company (Fairlawn, NJ, USA). HATU was purchased from Chemicals Testing & 
Calibration Laboratory (Singapore).  
Sheep blood red cells (SRBC) in Alsevers were purchased from BioMerieux 
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Australia Pty Ltd (Chatswood, NSW, Australia). Recombinant human intercellular 
adhesion molecular-1 (rhICAM-1) was provided by R&D Systems (Minneapolis, MN, 
USA). Bis-carboxyethyl-carboxyfluorescein, acetoxymethyl (BCECF, AM) was 
obtained from Molecular Probes (Eugene, OR, USA). Tris [hydroxymethyl] 
aminomethane (Tris) was from Mallinckrodt Baker Inc. (Phillipsburg, NJ, USA). 
2-(2-Aminoethyl)isothiourea dihydrobromide (AET), dextran and fluorescein 
diacetate (FDA) were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). 
Magnesium sulfate, calcium chloride dihydrate and Hank’s balanced salt solution 
(HBSS) were from Sigma Chemical CO. (St. Louis, MO, USA).  
Other materials used were as same as those listed in 3.2.1. 
4.2.1.2 Peptides 
The peptides (Table 4-1) were purchased from Multiple Peptide Systems (San 
Diego, CA, USA), Research Biolabs Pte Ltd (Singapore), AnaSpec Inc. (San Jose, CA, 
USA), GL Biochem (Shanghai) Ltd (Shanghai, China), SynPep (Dublin, CA) and JPT 
Peptide Technologies GmbH (Berlin, German).  
The peptide stock solution (40 mM) was prepared by dissolving peptides in 
sterile water containing DMSO and stored at －20℃. The peptide test solutions were 
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Table 4-1 Analytical data for the designed CD2 peptides 
Code Sequence HPLC purity (%) Theoretic mass 
cER Cyclo(1,12) PenERGSTLVAEFC >90% 1340.6 
cEL Cyclo(1,6) ERGSTL 95.9 643.7 
E1A Cyclo(1,6) ARGSTL 96.7 585.7 
R2A Cyclo(1,6) EAGSTL 98.83 558.6 
S4A Cyclo(1,6) ERGATL 96.36 627.7 
L6A Cyclo(1,6) ERGSTA 99.3 601.6 
cVL Cyclo(1,12) PenVYSTNGTRILC 96.0 1354.6 
cVY Cyclo(1,10) PenVYSTNGTRC 93.14 1129.3 
cAY Cyclo(1,10) PenAYSTNGTRC 93.15 1101.2 
cVR Cyclo(1,8) VYSTNGTR 90.1 878.96 
cYT Cyclo(1,6) YSTNGT >95% 623.6 
cIL Cyclo(1,12) PenIYDTKGKNVLC 99.5 1383.7 
cIY Cyclo(1,10) PenIYDTKGKNC 93.46 1170.4 
cIN Cyclo(1,8) IYDTKGKN 90.3% 919.46 
cYK Cyclo(1,6) YDTKGK >90% 693.4 
cAQ Cyclo(1,12) PenAQFRKEKETFC 97.6% 1515.8 
cQT Cyclo(1,10) PenQFRKEKETC 96.9% 1297.8 
cFE Cyclo(1,6) FRKEKE >90% 818.0 
  
Chapter 4. Biological activity of CD2-derived peptides 
 83 
4.2.1.3 Cell lines and cell culture 
OVCAR and Jurkat cell culture were carried out as described previously (refer 
to 3.2.2). 
4.2.2 Peptide synthesis 
Control peptide linear KGKTDAISVKAI (lKI) (mass=1230.5) was synthesized 
by an automatic peptide synthesizer (Pioneer Peptide Synthesizer, PerSeptive 
Biosystems Inc., MA, USA) using Fmoc solid-phase peptide synthesis strategy with 
PAL resin as solid support. In brief, 20% piperidine/DMF was used to remove the 
Fmoc protecting groups on the resin, and the Nα-Fmoc amino acid was preactivated 
by the coupling reagent HATU/DIPEA (1:1) before adding to the resin. Cycles of 
deprotection of Fmoc and coupling with the subsequent amino acids were repeated 
until the desired peptide-bound resin was obtained. The resin was then washed with 
DMF, DCM and methanol successively to remove the excess solvents and dried in 
vacuum. After cleavage by reacting with TFA/Thioanisole/EDT/H2O (95:2:2:1) for 
3hr, the filtrate was evaporated to nearly dry and cold ether (－20℃) was added to 
precipitate the peptide. 
4.2.3 OVCAR-Jurkat cell-cell adhesion assay 
A schematic diagram of OVCAR-Jurkat cell adhesion assay was illustrated in 
Figure 4-1. The Jurkat cells were washed with 0.5% BSA/HBSS twice and adjusted to 
3×106 cells/ml. Viability was greater than 95% as determined by trypan blue exclusion. 
BCECF–AM solution (1mg/ml in DMSO) was then added to the Jurkat cell 
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suspension to achieve the final concentration of 2µM and incubated at 37 ℃ for 
45min. Labeled Jurkat cells were washed three times and resuspended in 1% FBS/ 
RPMI 1640. BCECF-AM is able to cross the plasma membrane and accumulates in 
the cytoplasm of live cells with intact membranes. After cleavage of the protecting 
groups by intracellular esterases, the polar fluorophore (BCECF) remains trapped 
within the cell and gives a fluorescent signal. 
OVCAR cells were seeded onto 96-well culture plate at approximately 1.5×104 
cells/well and incubated at 37℃ for 72h to confluence. After a gentle wash with fresh 
media, 50µl of different concentration of peptides prepared in 1%FBS/RPMI 1640 
were added, and 1%FBS/RPMI 1640 containing the equivalent amount of DMSO 
(final concentration of 0.2% (v/v)) was used as control. After 30min incubation at 37
℃, 2×105 BCECF-labeled Jurkat cells were added to each well and incubated for 
another 45min. Non-adherent Jurkat cells were removed by washing thrice with PBS, 
while the adherent Jurkat cells were lysed with 2% Triton X-100 in 0.1 M NaOH. 
Fluorescence (FL) was quantified using a plate reader (Spectra Fluor, Tecan Group 
Ltd., Mannedorf, Switzerland) at 485/535nm and corrected for the reading of blank 
(OVCAR monolayers only).  
FL
 peptide treatment－FL blank 
Inhibition (%) = {1－ ------------------------------------}×100 
















Figure 4-1 Flow chart of OVCAR-Jurkat cell adhesion assay 
4.2.4 E-rosetting assay 
4.2.4.1 AET treatment of SRBC 
AET solution was freshly prepared by dissolving 0.402 g of AET in 10 ml 
distilled water, adjusting pH to 9.0 and filtering. Wash SRBC (stored in Alsever’s 
solution for up to 3 weeks) three times in sterile PBS by centrifuging at 2000 rpm for 
7 minutes at room temperature. Remove all the supernatant and any buffy coat on 
each wash. After the last wash, incubate the packed SRBC pellet with freshly prepared 
AET solution with a ratio of 1:4 (v/v) at 37°C for 15 min, inverting every 5 min to 
keep cells suspended. Wash five times with PBS until no residual haemolysis and the 
supernatant was clear. Resuspend the cells in RPMI 1640 medium supplemented with 
Microplate fluorometric assay 
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20% FBS to give a 10% AET-SRBC suspension and use within one week when stored 
at 4℃. A 0.5% suspension diluted in medium was used in E-rosette inhibition assay. 
4.2.4.2 Rosette inhibition 
The rosette inhibition test was performed in triplicate. Different concentration of 
peptide solutions and the control (containing only 0.2% DMSO) prepared in RPMI 
1640 were added to 100 µl of AET-treated SRBC and incubated at 37℃ for 30 min. 
Then 100 µl Jurkat cells (2×106 cells/ml) were added and incubated for another 15 
min. The cells were pelleted by centrifugation at 200g for 15 min at 4℃ and 
incubated at 4℃ for at least 1 h. The cell pellet was gently resuspended and the 
resulted E-rosettes were counted by a cell hemocytometer (Tiefe, Germany). No less 
than two hundred nucleated cells (Jurkat cells) were counted and attachment of five or 
more sheep erythrocytes to a Jurkat cell was viewed as rosette. The inhibition activity 
of the peptides was expressed as the percentage of non-RFC under peptide treatment 
compared with that without peptide treatment (control).  
                       Non-RFC% treated with peptides－Non-RFC%control 
Rosette inhibition (%)=  ------------------------------------------------------------×100 
                                RFC%control 
4.2.5 Cytotoxicity assay 
4.2.5.1 MTT assay for Jurkat cell viability 
The potential cytotoxicity of peptides to Jurkat cells was assessed using a MTT 
method described by Viale [112] with minor modification. Jurkat cells in logarithm 
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phase were adjusted to 5×105/ml and seeded in a 96-well plate at 100 µl/well. 100µl of 
peptide solution diluted in RPMI 1640 were added to each well to give a final 
concentration of 200 µM, which was the highest concentration in the cell adhesion 
assay. The plate was then incubated at 37℃ for 48h for long-term cytotoxicity study. 
In short-term cytotoxicity study, the cells were incubated 48h before peptide treatment 
for 1h, which is the exposure time of Jurkat cell to the peptides in the adhesion assay. 
Medium was used as blank, while 0.1% dextran and 0.1% SDS in medium were used 
as negative and positive control respectively. 20 µl of MTT solution (5mg/ml in PBS) 
was added to each well and incubated at 37℃ for another 4h. The plate was 
centrifuged at 1500 rpm for 5min and the supernatant was carefully aspirated before 
100 µl of DMSO was added to each well. The absorbance was measured at 590 nm 
using a plate reader (Spectra Fluor, Tecan Group Ltd., Mannedorf, Switzerland) and 
cell viability was expressed as the absorbance percentage of blank (treated with 
medium alone). 
4.2.5.2 FDA assay for OVCAR cell viability 
One major problem with MTT assay lies in that the intensity of MTT reduction 
varies considerably with cell line [99]. In our preliminary test, OVCAR monolayers 
showed quite low absorbance (<0.2) in MTT assay. Thus, a membrane integrity assay 
based on fluorescein diacetate (FDA) was applied to access OVCAR cell viability 
after exposure to high concentration of peptides [113].  
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OVCAR cells were trypsinized and seeded in a 96-well plate (15,000 cells/well). 
The plate was incubated at 37℃ for 24h to make the cells adhere to the bottom. The 
medium was changed to peptide solutions (final concentration of 200 µM in medium) 
or controls (medium, 1% SDS or 1% dextran), and incubated for another 48h. For 
short-term viability, OVCAR cells were incubated for 48h to nearly confluence before 
2h incubation with peptides or controls. The plate was washed with PBS and 200 µl of 
FDA solution (2 µg/ml in PBS) diluted from a stock solution (10 mg/ml in DMSO) 
was added to each well. The plate was incubated at 37℃  for 1h before the 
fluorescence was measured at 485/535 nm. The cell viability was expressed as the 
fluorescence percentage of peptide-treated samples compared to medium control.  
4.2.6 Jurkat cell-immobilized ICAM-1 adhesion 
4.2.6.1 Preliminary studies for LFA-1/ICAM-1 adhesion  
Since LFA-1/ICAM-1 binding is divalent cation dependent (Ca2+, Mg2+ or Mn2+), 
HBSS++/1%BSA buffer (HBSS containing 1%BSA, 2mM Mg2+ and 2mM Ca2+, 
adjusting pH 7.4) was used to ensure effective binding [114]. PMA was also used in 
our experiment to induce and enhance LFA-1 mediated adhesion. 
The effects of ICAM-1 coating solvents (PBS and pH 9.6 coating buffer) and 
ICAM-1 coating concentrations (1 µg/ml～10 µg/ml) were investigated with ELISA 
to determine the optimal binding conditions.  
In brief, rhICAM-1 stock solution (1mg/ml in sterile water) was diluted in PBS 
or 0.05 M carbonate/bicarbonate coating buffer (pH 9.6) to different concentrations. 
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50 µl/well of each concentration was added to a 96-well plate and coated at 4 ℃ 
overnight. The plate was washed twice in PBS and block with 1%BSA/PBS for 1h at 
room temperature before treated with CD54 mAb (1:2000) at 4 ℃ overnight. Then 
the plate was washed thrice with 1%BSA/PBS and incubated with anti-mouse 
IgG–HRP conjugate (1:1000) at 37 ℃  for 2h. After five time washing with 
1%BSA/PBS, ABTS substrate solution was added to react for 40 min before adding 
1% SDS to stop the reaction. Optical density (O.D.) readings were measured at 430 
nm. 
4.2.6.2 Peptide effects on LFA-1/ICAM-1 adhesion  
96-well plates (NunclonTM) were coated with 50 µl/well of rhICAM-1 (5 µg/ml 
in PBS) overnight at 4℃. Plates were washed three times and then blocked with 
HBSS++/1%BSA for 1h at room temperature. Peptides (200 µM in HBSS++/1%BSA), 
mAbs (5 µg/ml in HBSS++/1%BSA) or blanks (HBSS++/1%BSA alone, or containing 
0.2% DMSO) were added and incubated at 37℃ for 30min. Jurkat cells were labeled 
with BCECF as described under heterotypic adhesion assay (refer to 4.2.3) and 1.5×
105 cells resuspended in HBSS++/1%BSA were added to each well in the presence of 
50 ng/ml PMA. The plates were incubated at 37℃ for another 1h and unbound cells 
were removed by gently washing the plates three times with HBSS++/1%BSA. The 
bound cells were lysed with 2% Triton X-100 (in 0.1 M NaOH) and incubated at 37℃ 
for 1h before measured at 485/535 nm using a plate reader. For the total fluorescence 
of input cells, labeled Jurkat cell suspension was centrifuged at 2000 rpm for 5min 
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and the cell pellet was lysed with 2% Triton X-100 (in 0.1 M NaOH) at 37℃ for 1h. 
The fluorescence of aliquots of 1.5×105 cells/well represented the total input cells 
and the proportion of bound cells was expressed as the fluorescence percentage of 
input cells. 
4.2.7 Statistical analysis 
All experiments were repeated at least three times. Results were expressed as 
means ± standard deviation (S.D.). Inhibitory activity data were analyzed by one-way 
ANOVA with post-hoc Tukey test applied for paired comparisons (SPSS 10, SPSS Inc. 
Chicago, IL, USA). A difference between means was considered significant if the p 
value was equal or less than 0.05. 
4.3 Results and discussion 
4.3.1 Synthesis and purification of control peptide 
The resulted crude peptide was purified by preparative HPLC (Waters 600 HPLC 
system) on a reverse-phase C18 column (Inertsil, 10×250 mm, 5µm, 300 Å ), with a 
linear gradient of solvent A (0.1% TFA/H2O) and solvent B (0.1% TFA/ACN) 
(Figure 4-2(a)). The HPLC chromatogram showed that the purity was more than 90% 
and electro-spray ionization mass spectrometry (ESI-MS, Finnigon MAT) showed the 
correct molecular ion for the control peptide lKI (Figure 4-2 
(b)).
  




Figure 4-2 Synthesis of control peptide (a) purified by preparative HPLC. (b) ESI-MS 
spectrum of purified control peptide. 
4.3.2 Peptide inhibition activity 
The inhibition activity of peptides was investigated by the OVCAR-Jurkat 
heterotypic adhesion assay and traditional E-rosetting assay. The results from both 
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found that the inhibition activity was concentration dependent, which was more 
obvious for peptides with higher activity. 
4.3.2.1 Determination of MIS by truncation study 
The minimum inhibition sequence (MIS) was determined by truncating the 
parent 12-aa peptides and investigating the inhibitory activity of resulted peptides. 
The control peptide (lKI) showed very low inhibitory activity (<7%) at all 
concentrations and served as the negative control, while the active parent peptides 
(cER, cVL, cIL and cAQ) as positive controls. The minimum sequence with the 
activity significantly different from the negative control (p<0.05) but comparable to 
the positive control (p>0.05) can be viewed as MIS.  
Hexapeptide cEL was obtained by deleting 6 residues from C-terminal of the 
parent peptide cER and cyclized by peptide bond. It is interesting to note that loss of 
up to 6 residues showed even higher activity than the parent peptide. As shown in 
heterotypic cell assay (Figure 4-3 (a)), 200 µΜ cEL showed 45.6% inhibition while 
cER at same concentration only showed 39.5% activity. Similar trend was found in 
E-Rostting assay (Figure 4-3 (b)) that cEL showed higher activity (35.95%) than cER 
(29.7%) at the highest concentration. Statistical analysis revealed that, at all 
concentrations in both assays, cEL was significantly different from the negative 
control (p=0.00) but not significantly different from its positive control (p>0.05), 
suggesting hexapeptide cEL as the MIS of cER. 
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A decapeptide (cVY) and an octapeptide (cVR) were truncated from their parent 
peptide cVL by deleting two C-terminal residues. Both peptides have identical core 
sequence, but cVR was cyclized by peptide bond while cVY cyclized with disulfide 
bond introduced by Pen and Cys. Both truncated peptides showed similar inhibitory 
activity as the parent peptide in adhesion assays, indicating that the two C-terminal 
residues were not necessary for the inhibition activity and the introduction of Pen and 
Cys would not affect peptide activity. Statistical analysis showed that cVL, cVY and 
cVR belonged to a homogenous subset without significant difference (p>0.05), but 
significantly different from negative control (p<0.05). However, further truncation to 
hexapeptide (cYT) resulted in significant loss in activity, with about 20% activity in 
heterotypic assay and no more than 10% activity in E-rosetting assay at 200 µΜ 
(Figure 4-3). Statistical analysis suggested that cYT activity in E-rosetting assay was 
comparable to negative control (p>0.05) at all concentrations studied. Whereas, cYT 
activity in heterotypic assay (more than 50 µM) was significantly different from 
negative control (p<0.05), but not comparable to the positive control (p<0.05). 
Therefore, octapeptide cVR instead of hexapeptide cYT was the MIS in cVL.  
Τhe truncation study of cIL was also conducted from C-terminal. It was found 
that the biological activity of cIL series changed with the sequence length in a similar 
trend observed in cVL series. 200 µΜ of cIL showed 41% and 34% activity in 
heterotypic and E-rosetting assay respectively, and decapeptide (cIY) and octapeptide 
(cIN) that share the same core sequence retained the inhibition activity. However, 
further truncated hexapeptide (cYK) showed no more than 10% activity at the same 
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concentration (Figure 4-3). At all concentrations in both assays, cIY and cIN activity 
was comparable to the positive control (p>0.05) but was significantly different from 
the negative control (p<0.05), while cYK activity was comparable to the negative 
control (p>0.05) at most concentrations, indicating that octapeptide cIN was the 
minimally required sequence in cIL. 
The truncation of cAQ was conducted simultaneously at both ends; this made it 
different from the other three series in which the truncation was conducted from the C 
terminal residues. Deletion of one residue at both ends resulted in a decapeptide (cQT) 
and two residues from each terminal were cut off to give a hexapeptide (cFE). At the 
highest concentration, cQT maintained more than 90% activity of the parent peptide, 
while cFE only retained 55% (heterotypic adhesion assay) and 63% (E-rosetting assay) 
activity. At all concentrations studied, cQT activity was comparable to the positive 
control (p>0.05) but significantly different from the negative control (p<0.05), while 
cFE activity was significantly different from the positive control (p<0.05). Hence, 
































































Figure 4-3 MIS of peptides determined by (a) heterotypic cell adhesion assay and (b) 
E-rosetting assay. Peptide inhibition percentage was expressed as Mean±SD (n=3). 
4.3.2.2 Roles of residues by alanine scanning 
Due to the importance of charged residues in CD2-CD58 interaction, alanine 
scanning was applied to the potent hexapeptide cEL to investigate the role of some 
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replaced by Ala (A) and the inhibitory activity of resulted peptides (E1A, R2A, S4A 
and L6A) was studied. It was found that alanine mutation of charged residues caused 
significant loss of inhibition activity compared with the parent peptide cEL (p<0.05), 
and the most significant loss was resulted from the mutation of Ser (S4A). The 
activity of S4A was around 8% in the E-rosetting assay (Figure 4-4), which was 
comparable to that in the negative control peptide (p>0.05). Although the activity in 
heterotypic adhesion assay was a little higher (about 15%), S4A was still significantly 
different from the other three mutants (p<0.05) that belonged to a homogenous 
activity subset. The important roles of charged residues in maintaining inhibition 
activity can be explained by their involvement in β-turn structure or participation in 
salt bridge interaction with CD58 protein. 
It is known that Tyr86 in human CD2 serves as hot spot in ligand binding and its 
counterpart in rat CD2 is Tyr81. Therefore, peptides cIL (encomprising Tyr86) and 
cVL (encomprising Tyr81) were designed to mimic this important binding epitope. 
The deletion study indicated that both cYK and cYT lost significant activity although 
the Tyr was reserved in both sequences (Figure 4-3). We hypothesized that residues 
flanking the critical Tyr might stabilize the epitopes and thus contribute to the 
inhibition activity. Peptide cAY was therefore designed from bioactive cVY in which 
the flanking residue Val was replaced by Ala to verify our hypothesis. Reduced 
activity was revealed in cAY at all concentrations studied, which was significantly 
different from the parent peptide cVY (p<0.05). The activity of cAY was very similar 
to that of hexapeptide cYT with no more than 24% inhibition in heterotypic adhesion 
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and less than 10% inhibition in the E-rosetting (Figure 4-4). Statistical analysis 
indicated that cAY and cYT belonged to a homogeneous subset, which was 
significantly different from the positive cVY (p<0.05). The alanine mutation result 
indicated that the flanking residue, additional to the critical Tyr, was also important 




























































Figure 4-4 Peptide inhibitory activity in alanine scanning by (a) heterotypic adhesion assay 
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4.3.3 Cytotoxicity assay 
Cell viability is a prerequisite for performing cell functions including cell 
adhesion. Therefore, cell viability under high concentration of peptides (200 µM) 
needed to be studied before we moved on to investigate peptides’ effects on cell-cell 
adhesion. Short-term (1～2hr) and long-term (48hr) cell viability were used to 
investigate peptide potential toxicity to cells.  
As shown in Figure 4-5, cell viability of both Jurkat and OVCAR was 
generally unaffected by exposure to 200 µM of peptides up to 48h. The unaffected cell 
viability indicated that both Jurkat and OVCAR cells retained their normal cell 
functions upon exposure to peptides in the adhesion assay, thus the inhibitory activity 









































































































































short-term (2hr) long-term (48hr)
Figure 4-5 Peptide effects on cell viability. (a) Jurkat cell viability in MTT assay (b) OVCAR 
cell viability in FDA assay. Mean±SD (n=6) 
4.3.4 Jurkat cell-immobilized ICAM-1 adhesion 
4.3.4.1 ICAM-1 coating condition and PMA effect 
ELISA data showed that rhICAM-1 protein could be effectively coated on 
96-well plates both in PBS and coating buffer (0.05M carbonate/bicarbonate buffer, 
pH 9.6) (data not shown), thus PBS was used as coating solvent in the following tests. 
PMA played an important role in inducing and enhancing LFA-1/ICAM-1 
adhesion. In the absence of PMA, Jurkat cells could hardly adhere to the plate coated 
with rhICAM-1 in the range of coating concentration (1～10 µg/ml). However, in the 
presence of 50 ng/ml PMA, the percentage of bound Jurkat cells increased 
significantly and the adhesion was dependent on rhICAM-1 coating concentration 
(Figure 4-6).  
(b) 
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From the preliminary test results, 5 µg/ml of rhICAM-1 in PBS was used to coat 
the plates at 4℃  overnight before performing the Jurkat-immobilized ICAM-1 
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Figure 4-6 PMA effect on Jurkat-immobilized ICAM-1 adhesion. Mean±SD (n=6) 
4.3.4.2 Peptide effects on LFA-1/ICAM-1 adhesion 
In the presence of CD54 mAb, only 8.1% of the input Jurkat cells bound to the 
rhICAM-1 coated plate, which was much less than the bound cells in controls (59.5% 
in HBSS buffer and 58.0% in 0.2% DMSO), while the Jurkat cell binding was not 
obviously affected by CD2 mAb nor CD58 mAb (Figure 4-7). The antibody inhibition 
results indicated that Jurkat cell-immobilized ICAM-1 adhesion was mediated by 
LFA-1/ICAM-1 pathway instead of CD2/CD58 pathway.  
All test peptides showed no or little inhibition on the binding of Jurkat cells to 
the immobilized ICAM-1 (Figure 4-7), whereas they displayed different degree of 
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inhibitory activity in the binding of Jurkat cells to OVCAR monolayer (Figure 
4-3&4-4). Therefore, LFA-1/ICAM-1 adhesion results indirectly proved that the 
peptides inhibited cell adhesion by blocking CD2-CD58 interaction, or blocking 
CD2-CD58 firstly if other cell adhesion mechanism (such as LFA-1/ICAM-1) was 
























































































Figure 4-7 Peptide effects on Jurkat-immobilized ICAM-1 adhesion. Mean±SD (n=6) 
4.4 Conclusion 
Inhibitory activity of CD2-derived peptides was investigated by OVCAR-Jurkat 
heterotypic adhesion assay and E-rosetting inhibition assay to determine the MIS in 
parent peptides and to investigate the roles of certain residues. Biological activity 
studies indicated that hexapeptide (cEL) and octapeptide (cVR, cQT and cIN) served 
as the MIS for the four 12-aa parent peptides respectively. Meanwhile, the residue in 
the β-turn structure (Ser in cEL) and the residue flanking the hot spot (Var in cVL) 
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would be structurally and functionally important for CD2-derived peptides.  
Jurkat-immobilized ICAM-1 adhesion assay showed that all the test peptides did 
not inhibit LFA-1/ICAM-1 adhesion pathway, indicating that the CD2-derived 
peptides inhibited cell adhesion by modulating the CD2-CD58 interaction.  
Cytotoxicity assays indicated that the peptides were not toxic to test cells at a 
higher level of concentration, thus these active peptides would serve well as potential 
lead compounds for immunomodulation. 
  














STRUCTURE OF PEPTIDES BY NMR & MOLECULAR 
MODELING 
  
Chapter 5. Structure of peptides by NMR & molecular modeling 
 104 
5.1 Introduction 
A major goal of peptide conformation study is to investigate the 
structure-activity relationship (SAR) of biologically important peptides, which is 
helpful in understanding the mechanisms of biologically relevant conformation as 
well as designing potential pharmacological agents. 
Numerous studies suggest that peptide or protein activity is not only dependent 
on some critical function groups that bind to the receptors, but also dependent on the 
three-dimentional structure/conformation. Unlike proteins that fold into well-defined 
three-dimensional structures in solution, peptides are more flexible in solution and 
adopt unique structures only when bound to their appropriate receptors. Thus peptide 
conformation in solution is usually described in terms of the relative population of 
dominant conformers [115].  
Experimental and theoretical methods are complementary in determining peptide 
conformation in solution. Experimental methods, including nuclear magnetic 
resonance (NMR), circular dichroism (CD), hydrogen exchange, fluorescence 
resonance energy transfer, are widely used in peptide conformation studies. Molecular 
dynamics (MD) methods, on the other hand, are quite effective in searching the 
conformational space accessible to a peptide by providing molecular data including 
geometries (bond lengths, bond angles, torsion angles), energies (heat of formation, 
activation energy, etc.), electronic properties (moments, charges, ionization potential, 
electron affinity), spectroscopic properties (vibrational modes, chemical shifts) and 
bulk properties (volumes, surface areas, diffusion, viscosity, etc.). However, MD is 
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not able to estimate, precisely enough, the populations of various conformations. 
Therefore, MD must be supplemented by experimental data, especially the 
experimental NMR data [115].  
CD, NMR and MD are often combined for the conformational analysis of 
peptides [116, 117]. Here, structural studies based on CD and NMR techniques, 
together with restrained simulated annealing calculations of CD2 derived peptides 
were used to investigate SAR. 
5.1.1 Circular dichroism (CD) spectroscopy 
Circular dichroism (CD) is observed when an optically active compound absorbs 
left and right handed circularly polarized light at different extents. It is a rapid and 
convenient method for characterizing the secondary structures of peptides and 
proteins. CD is particularly powerful in monitoring conformational changes in 
proteins (monomer-oligomer, substrate binding, denaturation, etc) or estimation of 
secondary structural content in peptides [115]. 
CD spectroscopy is a widely used tool in the structural study of polypeptides and 
proteins because of its high conformational sensitivity and its small sample size 
requirement. CD signals in the far UV region (240～180 nm) reflect the peptide bond 
absorption, which is useful in predicting the secondary structures [118]. Although 
considerable information is known about the CD spectra of α-helix and β-sheets 
(Figure 5-1), the CD spectra of the pure type I and type II β-turns is hard to establish, 
because more than one form of β-turns are present in solution with different ratios. 
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The pure component CD curves of type I and type II β-turns were obtained from some 
pseudohexapeptides models using a newly developed algorithm [119]. The β-turn 
conformers were obtained by conformational deconvolution and the conformational 
weights calculated from the CD spectra were similar to those calculated from NMR 
[120]. Using these models, type I β-turns are characterized by positive bands at 
approximately 195 nm followed by negative bands greater than 200 nm, and type II 
β-turns often show positive bands around 205 nm. The open structures show negative 
peaks less than 200 nm and no clear maximum at 200～210 nm. 
 
Figure 5-1 CD spectra of typical secondary structures [118]. 
5.1.2 Nuclear magnetic resonance (NMR) spectroscopy 
The one-dimensional (1D) and two-dimensional (2D) NMR experiments are 
useful in determining the peptide structure in solution. Temperature gradient 
measurements with 1D NMR are useful to probe solvent accessibilities of residues 
and also to monitor the temperature-induced conformational changes in protein. In 
principle, amide protons show marked changes in their chemical shift values with 
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temperature because heating causes increase in thermal motion in the protein and thus 
weaken the hydrogen bond formed by amide protons. Amide protons that are not 
hydrogen bonded and exposed to the solvent show larger changes in the chemical shift 
values than those involved in hydrogen bonding in the protein molecule. Thus, the 
temperature gradients of amide protons serve as indicators for hydrogen bonding, and, 
in general, temperature coefficient values more positive than － 4 ppb/K are 
indicative of the involvement of the amide proton(s) in intramolecular hydrogen 
bonding [121, 122].  
Various 1H-1H 2D NMR techniques are widely used to determine peptide 
structure in solution. Double-quantum filtered correlation spectroscopy (DQF-COSY) 
experiment correlates protons that are J-coupled to one another and the coupling 
constants between NH and CαH protons (3JHN-Hα) can be measured [123, 124]. Total 
correlated spectroscopy (TOCSY) yields long range as well as short range correlations 
within a spin system but the cross peak intensity is not an indicator of distance [124].  
Nuclear overhauser enhancement spectroscopy (NOESY) is useful for 
determining protons that are close in space but not closely connected by chemical 
bonds. A NOESY spectrum yields through space correlations via the nuclear 
overhauser effect (NOE) [124, 125]. Also useful for determining spacially connected 
protons, ROESY (rotating frame overhauser enhancement spectroscopy) is especially 
useful for cases where NOESY signals are weak [125, 126]. The intensity of 
NOEs/ROEs indicates the distance between the protons, thus shows the connectivity 
between residues in a peptide within a distance range (1.9～5.0 Å). Therefore, the 
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cross peak signals in NOESY or ROESY spectra can be used for obtaining the 
restraints in MD calculations. 
In summary, the basic structural information comes from interproton nuclear 
overhauser effects (NOESY or ROESY spectra) and assumes the form of the so-called 
“contact map” indicating the pairs of protons that are close to one another in space. In 
addition, coupling constants (3JHN-Hα) contain information about the average values of 
the peptide backbone torsional φ angles. The restraints derived from these data make 
it possible to determine protein structures via restrained molecular dynamics 
calculations [115]. 
5.1.3 Molecular dynamics (MD) simulation  
For peptides that could have several conformations in solution, CD spectra 
usually provide the predominant conformation, while the more sensitive NMR can 
detect possible conformations. The correlation of quantitative CD and NMR data is 
lacking and two methods can yield different types of conformation on the same 
structure. Therefore, MD simulation based on NOEs or ROEs constraints was carried 
out to determine the complete conformational sets of models, followed by comparison 
with experimental CD and NMR data to identify the most feasible low energy 
conformation. 
Secondary structure is typically recognized by specific backbone torsion angles 
and specific mainchain hydrogen bonds. There are three repeating torsion angles phi 
(φ), psi (ψ) and omega (ω) along peptide backbone chain (Figure 5-2). ω angle tends 
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to be planar (0 or 180o), which leaves φ and ψ for flexible folding of the chain. 
Repeating values of φ and ψ along the chain result in regular structure such as helix, 
β-sheet or β-turns. β-turns usually involve four residues with hydrogen bonding from 
C=O of residue 1 (i) to the N-H of residue 4 (i+3), and different torsion angles (φ and 
ψ) of residue 2 (i+1) and 3 (i+2) determine the types of β-turns. The typical backbone 
torsion angles of various identified β turn types were listed in Table 5-1 [127]. It is 
notable that a fairly wide deviation from these theoretical torsion angles was 
permitted (±30°). The analysis of 3899 β-turns by Hutchinson and Thornton provided 
the amino acid preference (Table 5-2) for the 4 positions (i, i+1, i+2 and i+3) in the 




Figure 5-2 Illustration of dihedral angles in peptides. The backbone atoms of nitrogen, carbon, 
oxygen and hydrogen are represented by green, gray, red and black circles respectively. 
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Table 5-1 Typical backbone torsion angles of various idealized β turn types [127]. Types 
I’-III’ are the mirror images of type I-III turns respectively. 
 
Table 5-2 Amino acid preference in most common β-turns [70] 
Type Residue 1 (i) Residue 2 ( i+1) Residue 3 (i+2) Residue 4 (i+3) 
I Asn, Asp, Cys, Ser Pro, Glu, Ser Asp, Asn, Ser, Thr Gly 
II Pro, Tyr Pro, Lys Gly, Asn Pro, Cys, Ser, Lys 
VIII Pro, Gly  Asn, Asp, Val,  Pro, Thr 
I’ Tyr, Val Asn, Asp, Gly Gly Lys 
II’ Tyr Gly Asp, Asn, Ser Thr, Gly 
5.2 Materials and methods  
5.2.1 Materials 
Deuterium oxide (D2O) and sodium 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS) were purchased from Aldrich Chemical Co., Inc (Milwaukee, MI, USA). 
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5.2.2 CD measurement  
CD experiments were carried out on a Jasco J-815 spectropolarimeter, equipped 
with the standard data analysis program (Jasco Inc., Tokyo, Japan). Peptides were 
dissolved in deionized water to a final concentration of 0.5～2 mM at room 
temperature. A quartz cell with a 0.1 cm path length was used and spectra were 
recorded with a 1.0 nm bandwidth and resolution of 0.1 nm over the wavelength range 
of 190 to 260 nm. A total of 3 scans were averaged and the raw data was manipulated 
by smoothing and subtraction of buffer spectra. CD values were expressed as the 
mean residue molar ellipticity (θ). The ellipticity around 201 nm is attributed to pi-pi* 
minima and ellipticity around 222 nm is often the result of n-pi* transition.  
5.2.3 NMR experiments 
The samples were prepared by dissolving 3～4 mg of the peptides in 0.6 ml of  
H2O/D2O (9:1) with DSS as chemical shift standard at the pH with the best 
dispersion. 
1D and 2D NMR experiments were performed on 300 MHz Bruker DRX 
spectrometer (Bruker, Zurich, Switzerland) equipped with a 5-mm broad-band inverse 
probe at a proton frequency of 300.3414 MHz. All experiments were carried out by 
the presaturation of water during relaxation delay resulting in good solvent 
suppression. Data were collected by the time-proportional phase increment (TPPI) 
method with the sweep width of 10 ppm. Spectra were processed with XWINNMR 
software. The proton chemical shifts were referenced with internal standard DSS. 
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Mixing time in TOCSY and NOESY was 70～80 ms and 300 ms respectively, while 
spin-lock time in ROESY was 300 ms.  
After identified by TOCSY, the chemical shift of each amide proton was 
measured by collecting data from 283K to 308K at 5K intervals using 1D NMR. The 
temperature coefficient of each amide proton was expressed as the gradient (△δ/△Κ) 
of the line with the chemical shift (y-axis) against temperature(x-axis). Amide proton 
with a temperature coefficient more positive than －4 ppb/K was considered to be 
solvent-shielded or participate in intramolecular hydrogen bonding. 
Coupling constants (3JHN-Hα) were measured from the DQF-COSY spectra. 
Intensities of ROE/NOE were assigned as strong, medium and weak with upper and 
lower boundaries of distance for dNα (i, i), dαN (i, i +1) and dNN (i, i +1), 1.9～3.0, 
2.2～3.6 and 3.0～5.0 Å, which were used for later molecular dynamics simulations. 
5.2.4 NMR-restrained molecular modeling 
After an initial minimization and dynamics at 300 K with NMR restraints, the 
peptides were cyclized by peptide bond or disulfide bond based on the MD trajectory 
analysis (both energy and distance). Next, the molecule was heated to 900 K to 
determine the possible conformational sets with low energy from trajectory analysis 
(backbone RMSD less than 1 Å belongs to the same conformation set). Then a 
representative conformer from each set was cooled to 300 K at steps of 100 K. The 
low energy conformation near the end of the time-energy trajectory analysis was 
selected for each temperature and then subjected to further dynamics. Dynamics at 
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300 K and 900 K were carried out for 10,000 femtoseconds, while dynamics at other 
temperatures were carried out for 5000 femtoseconds. Peptide bonds were tethered at 
all temperatures except at 300 K. After dynamics at 300 K, an average conformation 
of each set was obtained and subjected to conformational analysis to determine the 
possible secondary structure. 
5.3 Results and discussion  
5.3.1 SAR study of hCD2 derived peptides 
5.3.1.1 CD analysis of cAQ and cIL series 
CD spectra of cAQ and cIL series peptides were shown in Figure 5-3. Linear 
control peptide (lKI) showed a negative peak below 200 nm (around 198 nm), which 
suggested an open or unordered conformation in solution. In contrast, the cyclic 
peptide cAQ and its two-residue truncation cQT exhibited quite similar CD spectra 
with a negative maximum at 204 nm and 203 nm respectively (Figure 5-3(A)), 
indicating a type I β-turn structure in both peptides. Further, upon truncation of the 
peptide to hexapeptide cFE, the negative maximum shifted to 201 nm, suggesting less 
percentage of β-turn in cFE. Therefore, CD data suggested that truncation of cAQ to 
cQT did not affect the structure significantly, while further truncation to cFE resulted 
in loss of structure. 
As shown in Figure 5-3 (B), the negative band of parent peptide cIL was at 208 
nm, indicating large percentage of type I β-turn in peptide structure. Truncation of two 
residues at the C terminal resulted in two peptides, one was cyclized by introducing 
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disulfide bond (cIY) and the other was directly cyclized by peptide bond (cIN). CD 
data showed that cIY lost stable conformation with the negative maximum shifting to 
198 nm, while cIN maintained much β-turn structure with the negative maximum at 
205 nm and at meantime showed some β-strand character with a negative shoulder 
appeared around 220 nm. Thus, the peptide bond might be more efficient than 
disulfide cyclization in maintaining peptide secondary structure, though there was no 
obvious difference in the biological activity of cIY and cIN. Further truncation to 
hexapeptide (cYK) resulted in open structure with the negative maximum less than 
200 nm (at 197 nm), even if it was cyclized by peptide bond.  
CD spectra suggested that compared to the hexapeptides, cQT and cIN maintain 
stable β-turn structure in solution, which might explain their higher inhibitory activity 
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Figure 5-3 CD spectra of human CD2 derived peptides in H2O. (a) cAQ series (0.5 mM)  
and control peptide lKI (2 mM) (b) cIL series (1 mM) 
5.3.1.2 NMR structural determination of cQT and cIN 
As described earlier that biological study indicated cQT and cIN as MIS of cAQ 
and cIL respectively, their conformations need to be determined to investigate the 
relationship between structure and activity. Although CD spectra give some 
information of secondary structure, it is poor in predicting peptide structure. Therefore, 
various 2D NMR (DQF-COSY, TOCSY, NOESY or ROESY) experiments were 
carried out to determine the structure of these two MIS peptides.  
The NMR spectrum of cQT was well dispersed at 298K (Table 5-3). The amide 
region of ROESY spectrum of cQT showed NH-NH cross peaks of K5-R4, K5-E6, 
E6-K7 and R4-K7 (Figure 5-4), suggesting the presence of folded or turn structure at 
R4-K5-E6-K7. The coupling constant values of the amide protons were in the range 
(B) 
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of 7-9 Hz (Table 5-3), indicating the rapid interconverting conformation of the 
peptide. 
Table 5-3 Chemical shift and coupling constant data for cQT peptide in water at 298K 
Residue NH αH βH γH Other protons 3JHN-Hα (Hz)  
Pen1  
 
     
Gln2 8.382 4.351 1.962, 1.807 2.233  8.49 
Phe3 8.556 4.572 2.927   7.11 
Arg4 8.329 4.196 1.685, 1.584 1.439 δH 3.06, NH 7.173 7.43 
Lys5 8.505 3.967 1.718, 1.588 1.305 εΝΗ 7.549 7.38 
Glu6 8.314 4.032 2.04 2.317  8.04 
Lys7 8.118 4.235 1.71, 1.555 1.287 εΗ 2.872; εΝΗ 7.533 7.28 
Glu8 8.862 4.304 1.841 2.124  8.31 
Thr9 8.142 4.345 4.119 1.065  8.98 
Cys10 8.429 4.484 3.225, 3.011   8.49 
 
       
(A) 
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Figure 5-4 1H NMR assignment of peptide cQT in H2O/D2O (9:1) at 298K. (A) Fingerprint 
region of TOCSY spectrum with 70 msec mixing time. (B) Fingerprint region of ROESY 
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The backbone and side chain protons of peptide cIN were assigned and listed in 
Table 5-4. The chemical shift spread of amide resonance was less than 0.5 ppm, 
indicating a flexible conformation of the peptide. The coupling constants of most 
residues were in the range of 7-9 Hz, indicting the β-sheet structure. The ROESY 
spectrum of cIN revealed NH-NH connections of T4-K5, G6-K7, K7-N8 and I1-Y2 
(Figure 5-5), which suggested the presence of turn or folded structure at 
T4-K5-G6-K7 or K7-N8-I1-Y2. 
Table 5-4 Chemical shift and coupling constant data for cIN peptide in water at 298K 
Residue NH αH βH γH Other protons 3JHN-Hα (Hz) 
Ile1 7.908  
 
3.959 1.611 1.106, 0.651  7.26 
Tyr2 8.064 4.554 3.079   8.04 
Asp3 8.244 4.587 2.777   8.49 
Thr4 8.161 4.237 4.155 1.139  7.26 
Lys5 8.299 4.204 1.743, 1.606 1.346 εΝΗ 7.542  7.46 
Gly6 8.349 3.863    11.40 
Lys7 8.194 4.204 1.75, 1.595 1.325 εΝΗ 7.542 8.16 
Asn8 8.069 4.434 2.883 2.635 ΝH 7.542 7.60 
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Figure 5-5 1H NMR assignment of peptide cIN in H2O/D2O (9:1) at 298K. (A) Fingerprint 
region of TOCSY spectrum with 70 msec mixing time. (B) Fingerprint region of ROESY 
spectrum with spin-lock time of 300 msec. (C) Amide region of ROESY spectrum. 
5.3.1.3 Conformation of peptide cQT and cIN 
From ROE-restrained MD simulation, the low energy structures that represented 
the conformation of peptides were obtained. The resulted backbone dihedral angles 
were used to determine the type of β-turn in peptides. 
ROE-restrained MD resulted in 9 energetically favorable conformers in cQT, 
which were then subjected to superimpose to check the convergence. All structures 
presented a well defined β-turn spanning residues R4-K5-E6-K7, and the average 
RMSD of backbone atoms was 0.7697±0.1999 Å. The dihedral angles around K5 
and E6 (Table 5-5) suggested that the β-turn in cQT was type I (e.g. structure II) or 
(C) 
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type III (e.g. structure V), although the amino acid preference (Lys residue at both 
second and fourth positions) suggested a possible type II β-turn. A representative 
conformation (structure II) was shown in Figure 5-6 (a). The existence of β-turn 
structure spanning R4-K5-E6-K7 was supported by NH-NH ROEs at R4-K5, K5-E6, 
E6-K7 and R4-K7, as well as the Ηα-ΝΗ ROEs at R4-K5, K5-E6 and E6-K7 in NMR 
study (Figure 5-4). 
Table 5-5 The backbone dihedral angles at R4-K5-E6-K7 in MD-based conformation of 
peptide cQT  
Structure φi+1 ψi+1 φi+2 ψi+2 
I -73.8 -53.5 -82 -29.5 
II -56.5 -38.6 -94.5 11.8 
III -61.5 -37.3 -70.6 -27 
IV -57.6 -34.3 -74.9 -51.8 
V -57.3 -34.2 -70.4 -26.3 
VI -55 -38.2 -78.8 -9.6 
VII -56.6 -37.5 -74.5 -51.5 
VIII -87.4 -58.8 -80.6 -4.1 
IX -62.7 -49.9 -75.9 -29.1 
Average -63 -42 -78 -24 
MD study of cIN also led to 9 energetically favorable conformers, which were 
characterized by a β-turn at D3-T4-K5-G6 (Figure 5-6(b)). The average RMSD of the 
backbone atoms of all the nine structures was no more than 0.5 Å (0.4075±0.1091 Å), 
indicating the stable nature of the β-turn conformation. The backbone dihedral angles 
around D3-T4-K5-G6 (Table 5-6) suggested a type I β-turn, and the residue positions 
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(Asp(i) and Gly (i+3)) also supported the type I β-turn. The conformation obtained 
from MD simulation was consistent with the NMR structure, which showed NH-NH 
connection at T4-K5, Hα-ΝΗ connection at K5-G6, as well as the long range cross 
peaks between D3 and K5 (Figure 5-5). 
Table 5-6 The backbone dihedral angles at D3-T4-K5-G6 in MD-based conformation of 
peptide cIN  
Structure φi+1 ψi+1 φi+2 ψi+2 
I -53.5 -17.1 -89.6 67.3 
II -88.6 -39.5 -85.6 84.2 
III -57.6 -26.9 -85.5 67.8 
IV -61.1 -26 -87.1 56.2 
V -52.6 -21.8 -77.5 55.1 
VI -76.6 -30.2 -89.5 74.5 
VII -54.3 -33.3 -86.8 78 
VIII -64.3 -20 -83.3 68.9 
IX -67.5 -20.7 -92.9 64.6 
Average -64 -26 -86 69 
 
Figure 5-6 Ribbon presentation of peptide structure from NMR-MD for (a) cQT and (b) cIN 
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5.3.1.4 SAR of cAQ series and cIL series peptides 
From structural studies by CD, NMR and MD simulation, octapeptide cQT and 
cIN truncated from cAQ and cIL exhibited a stable β-turn at R4-K5-E6-K7 and 
D3-T4-K5-G6 (Figure 5-6) respectively. The β-turns in peptides were comparable to 
the native β-turns in human CD2 sequence (R48-K49-E50-K51 and 
D87-T88-K89-G90) from which the peptides were derived. After truncation, cQT and 
cIN retained the critical β-turn structure that was responsible for the high inhibitory 
activity observed in biological assays, thus functioned as the MIS peptides. 
5.3.2 SAR study of rCD2 derived peptides 
5.3.2.1 CD analysis of cVL series and cEL alanine mutations 
As shown in Figure 5-7(A), parent peptide cVL exhibited a negative peak around 
205nm, indicating a type I β-turn structure in solution. Truncation of two residues on 
C terminal (cVY) seemed to increase the percentage of β-turn structure with the 
negative maximum moving to 207 nm, while alanine mutation (cAY) resulted in some 
loss of β-turn structure as the negative band shifted to 203 nm. A negative peak (203 
nm) and a weak negative shoulder (219 nm) were observed on octapeptide cVR that 
had the same core sequence as cVY but cyclized by peptide bond, which looked like a 
mixture of β-turn and β-strand. Further truncation to hexapeptide (cYT) exhibited a 
relative flat CD spectrum around 200～220 nm, suggesting a more random structure. 
Mutation of Val (cAY) or direct cyclization of Val with Arg (cVR) resulted in lower 
population of β-turn structure as CD peaks shifted toward short wavelength, while 
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deletion of Val (cYT) even led to loss of β-turn structure, suggesting that Val flanking 
the critical residue of Tyr was very important for peptide structure stability. 
Potent peptide cEL revealed negative maximum at 206 nm, suggesting large 
percentage of a type I β-turn in structure. However, the negative peaks of all the 
alanine mutations shifted to 201～202 nm (Figure 5-7 (B)), suggesting alanine 
mutagenesis reduced the percentage of β-turn in peptide structure, which might 
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cEL E1A R2A S4A L6A
Figure 5-7 CD spectra of rat CD2 derived peptides in H2O. (A) cVL series (1 mM)  
(B) cEL (2 mM) and alanine mutations (0.5 mM). 
5.3.2.2 NMR structural determination 
5.3.2.2.1 NMR study of cVR 
Biological assays indicated peptide cVR as the MIS in cVL series, thus the 
structure of cVR was determined by NMR. The NMR spectrum of cVR was well 
dispersed and all the amide resonance could be assigned without ambiguity (Table 
5-7). Most residues had a coupling constant between 7-9 Hz, indicating the rapid 
conformational conversion at NMR time scale. The ROESY spectrum of cVR 
revealed NH-NH connections of Y2-S3, T4-N5, G6-T7, T7-R8 and G6-V1 (Figure 
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Table 5-7 Chemical shift and coupling constant data for cVR peptide in water at 298K 
Residue NH αH βH γH Other protons 3JHN-Hα (Hz) 
Val1 8.022  
 
3.791 1.758 0.754, 0.597  7.26 
Tyr2 7.901 4.576 3.1, 2.988   8.60 
Ser3 8.208 4.471 3.901, 3.82   7.21 
Thr4 8.251 4.225 4.134 1.185  7.82 
Asn5 8.088 4.786 2.854   8.47 
Gly6 8.160 4.021, 3.864    11.37 
Thr7 7.916 4.408 4.337 1.136  8.55 
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Figure 5-8 1H NMR assignment of peptide cVR in H2O/ D2O (9:1) at 298K. (A) Fingerprint 
region of TOCSY spectrum with 70 msec mixing time. (B) Fingerprint region of ROESY 
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5.3.2.2.2 NMR study of R2A and S4A 
Biological assays suggested that alanine mutagenesis of cEL resulted in loss of 
inhibitory activity, in which S4A caused the most significant reduction. Therefore, 
R2A and S4A were chosen for structural analysis to investigate the SAR of alanine 
mutations. 
The variable temperature study of the amidic protons was carried out to 
determine the temperature coefficients. In all cases, the chemical shifts varied linearly 
towards upfield with temperature (data not shown), indicating no major 
conformational changes were present over the range of temperature studied. The 
amide regions of 1D NMR spectra of both peptides showed good dispersion in 
chemical shifts over a range of around 1ppm (Table 5-8 & 5-9), indicting the 
well-defined conformation in solution. 
Table 5-8 Proton chemical shifts, coupling constants and amide temperature coefficients for 
R2A peptide in water at 298K  
Residue NH αH βH Other protons 3JHN-Hα (Hz) △δ/△T (ppb/K) 
Glu1 7.714  
 
4.384 2.371, 1.943 γH 2.149 7.67 -1.9 
Ala2 8.184 4.378 1.369  5.21 -5.9 
Gly3 8.799 4.17, 3.768   10.35 -7.7 
Ser4 8.741 4.567 4.093, 3.888  7.52 -5.9 
Thr5 8.218 4.41 4.324 γH 1.224 7.29 -4.8 
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Table 5-9 Proton chemical shifts, coupling constants and amide temperature coefficients for 
S4A peptide in water at 298K  




Glu1 7.932 4.212 2.32, 1.91 γH 2.037 7.08 -2.8 
Arg2 8.019 4.193 1.745 γH 1.472;δH 3.126;ΝΗ 7.218 6.03 -3.1 
Gly3 8.859 3.978, 3.647   10.69 -8.3 
Ala4 8.751 4.378 1.374  7.26 -6.9 
Thr5 8.048 4.388 4.232 γH 1.13 8.13 -5.4 
Leu6 8.43 4.115 1.579 δH 0.818 6.08 -7.2 
 
The dNN (i, i+1) cross peaks in R2A ROESY spectrum revealed the connections 
between S4-T5, L6-E1 and E1-A2 (Figure 5-9), suggesting the presence of β turn 
around these residues. The low temperature-dependent coefficient (△δ/△T) of E1 
(－1.9 ppb/K) indicated that the amide proton of E1 was strongly intramolecular 
hydrogen bonded thus stabilized a β-turn at E1-A2-G3-S4 by introducing a strong 
intramolecular hydrogen-bonding interaction between the turn residues. Moreover, the 
coupling constants of A2 (5.2 Hz) and G3 (10.4 Hz) were close to those expected for a 
type I β-turn (3JHN-Hα of 4 Hz and 9 Hz for the i+1 and i+2 turn residues respectively), 
suggesting a type I β-turn at E1-A2-G3-S4. 
The NOESY spectrum of S4A showed NH-NH cross peaks of A4-T5, T5-L6 and 
L6-E1 (Figure 5-10), suggesting the possibility of turn around residues A4, T5, L6 
and E1. The low temperature coefficient (△δ/△T) in E1 (－2.8 ppb/K) and R2 (－
3.1 ppb/K) indicated these two residues were strongly solvent shielded or involved in 
intracellular hydrogen bonds. However, the coupling constants of most of the amide 
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protons were in the range of 6-8 Hz suggestive of rapidly interconverting conformers 









Figure 5-9 1H NMR assignment of peptide R2A in H2O/D2O (9:1) at 298K. (A) Fingerprint 
region of TOCSY spectrum with 70 msec mixing time. (B) Fingerprint region of ROESY 
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Figure 5-10 1H NMR assignment of peptide S4A in H2O/D2O (9:1) at 298K. (A) Fingerprint 
region of TOCSY spectrum with 70 msec mixing time. (B) Fingerprint region of NOESY 
spectrum with spin-lock time of 300 msec. (C) Amide region of NOESY spectrum. 
5.3.2.3 NMR-restrained molecular modeling  
5.3.2.3.1 Conformation of cVR 
ROE-restrained MD resulted in one possible structure characterized by a β turn 
at Y2-S3-T4-N5 (Figure 5-11). The average backbone RMSD of the 10 superimpose 
was less than 0.5 Å (0.3092±0.1040 Å), indicating the stable nature of the 
conformation. However, the average dihedral angles of S3-T4 residues were －63°, 
－30°, －76°, 105°, with the ψ angle of T4 (105°) deviating from an ideal type I β 
turn. This predicted β turn was consistent with the NMR study, which showed NH-NH 
connection at Y2-S3 and T4-N5, Hα-ΗΝ and Ηβ-ΗΝ connections at S3-T4 and T4-N5 
(C) 
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(Figure 5-8). 
According to amino acid preference analysis (Table 5-2), sequence S-T-N-G can 
form stable type I β-turn, which was shown in the parent peptide cVL at 
S4-T5-N6-G7 and native rCD2 fragment at S82-T83-N84-G85. On the other hand, 
truncated octapeptide cVR revealed a β-turn with one residue shifting to N-terminal 











Figure 5-11 Representative structure of peptide cVR obtained from NMR-MD 
5.3.2.3.2 Conformation of R2A and S4A 
Upon minimization and molecular dynamics, only one conformation family that 
satisfied the NMR data was identified in R2A and the average backbone RMSD of the 
10 structures in this family was 0.2414 Å±0.0415 (Figure 5-12). The dihedral angles 
around A2-G3 (－102°, 113°, 86°, －75°) and around L6-E1 (－71°, －45°, －143°, 
－91°) suggested a type II β-turn at E1-A2-G3-S4 and a type I β-turn at T5-L6-E1-A2, 
although the dihedral angles deviated slightly from the ideal β-turns. These β turns 
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were supported by the wide connections of E1 protons (ΗΝ, Hα, Ηβ, Ηγ) with A2 
amide proton, as well as ROE connections between A2-G3, G3-S4 and L6-E1 (Figure 
5-9).  
The conformation derived from MD simulation of R2A indicated the 
intra-molecular hydrogen bond between amide proton of E1 and carboxyl oxygen of 
S4, which was consistent with the low temperature coefficient of amide E1. This 
stable intra-molecular hydrogen bond was supposed to stabilize the β-turn around 
E1-A2-G3-S4. Additional hydrogen bonds were suggested between NH of L6 and 
C=O of S4, NH of S4 and C=O of A2, as well as between side chain OH of S4 and its 
main chain C=O in the proposed model, which might contribute to stabilizing the 
overall conformation. 
Therefore, R2A was consisted of two β turns, a possible type I turn at 
T5-L6-E1-A2, and a type II turn at E1-A2-G3-S4 that was supported by amino acid 
preference prediction at G3 and S4 (Table 5-2).  
 
Figure 5-12 Superimposition of 10 NMR-derived structures in peptide R2A. Only heavy 
atoms are shown. The mean backbone RMSD for the 10 structures is 0.2414 Å±0.0415. 
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In case of S4A, four sets of energetically possible conformations were identified 
after minimization and dynamics. The average structure (I-IV) was taken from each 
family as a representative. Except for structure IV, which was more likely an open 
structure, the other three (I, II and III) displayed possible β-turn structure. From the 
backbone dihedral angles (Table 5-10), structure I was characterized by two type I 
β-turns (T5-L6-E1-R2 and G3-A4-T5-L6 respectively), structure II had a type I β-turn 
(T5-L6-E1-R2) and a type II’ β-turn (R2-G3-A4-T5), and structure III had only one 
type I β-turn at T5-L6-E1-R2. However, these dihedral angles deviated from the ideal 
β-turns.  
The existence of β-turn at T5-L6-E1-R2 in I-III was supported by the NH-NH, 
Hα-ΝΗ and Ηβ-NH NOEs connections between T5-L6, L6-E1 and E1-R2, while the 
other possible β-turn around R2-G3-A4-T5 or G3-A4-T5-L6 was supported by the 
NOEs of R2-G3 (Hα-ΝΗ), G3-A4 (Hα-ΝΗ), A4-T5 (NH-NH) and T5-L6 (NH-NH, 
Hα-ΝΗ, Ηβ-NH) (Figure 5-10). 
Therefore, S4A displayed mixed conformers of β-turn and open structure in 
solution. The structures of II and IV were chosen to represent the mixed 
conformations in S4A (Figure 5-13). These possible conformations co-existed or 
transited to one another quickly in solution, which could explain the β-turn structure 
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Table5-10 The backbone dihedral angles in the conformation of peptide S4A 


























Figure 5-13 Representative structure of peptide S4A using NMR-MD. (a) Structure II with 
possible β turns spanning T5-L6-E1-R2 and R2-G3-A4-T5. (b) Structure IV with open 
structure. 
5.3.2.4 SAR of cVL series and cEL alanine mutations 
Structural studies were used to investigate the SAR of rCD2 derived peptides. 
CD, NMR and MD results indicated that MIS peptide cVR truncated from cVL 
retained stable β turn structure in solution, which might account for its high biological 
activity. It was noted that cVR displayed a β turn (Y2-S3-T4-N5) with one residue 
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shift compared to the native rCD2 sequence (S-T-N-G) it derived from. However, 
alanine mutation of the residue flanking the β turn structure (cAY) might affect the 
stability of β turn or destroy the β turn, which was implicated by the CD spectra, thus 
resulted in significant loss of biological activity.  
The alanine mutagenesis on cEL showed that mutagenesis at different residues 
resulted in different effects on the peptide conformation as well as peptide activity. 
The parent peptide cEL exhibited two β turns, one at R2-G3-S4-T5 that was 
consistent with the native rCD2 β turn at R34-G35-S36-T37, and the other one 
T5-L6-E1-R2 was induced by cyclization [51]. R2A maintained the basic β turn 
structure but with one residue shift in the important turn  (E1-A2-G3-S4 compared to 
R2-G3-S4-T5), indicating that the integrity of β turn at R2-G3-S4-T5 was critical for 
the high activity in cEL. On the other hand, S4A displayed flexible conformation 
(possible β turn or open structure) when mutated at the turn residue of Ser. Therefore, 
S4A showed the least activity possibly due to the loss of stable β turn conformation in 
solution. The SAR study of alanine mutations suggested that charged residues, 
especially when serving as turn residues, were critical for the activity of β turn 
peptides. 
5.4 Conclusion 
To elucidate the structure-activity relationship in CD2-derived peptides, 
structural studies were performed on some selected peptides (including MIS peptides 
and the alanine mutations) using CD, NMR and MD. The data from these experiments 
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were well correlated and indicated the important role of β turn in the inhibitory 
activity of CD2-derived peptides. The MIS peptides (cQT, cIN and cVR) adopted 
stable β-turn structures in solution that might account for their high biological activity. 
On the other hand, mutations of the β-turn residues (R2A and S4A) as well as the 
residue flanking β-turn (cAY) were functionally deleterious, as the stability of β-turn, 
or the β-turn itself might be destroyed upon mutation of these important residues. 
Hence, the SAR study confirmed our hypothesis that β-turn played an important 
role in the inhibitory activity of CD2-derived peptides by mimicking the binding 
epitopes as the native sequence.





















Four series of peptides (cER, cVL, cAQ, cIL) were designed from critical ligand 
binding epitopes on CD2 protein to modulate CD2-CD58 interaction. To investigate 
the structure-activity relationship (SAR) of the CD2 derived peptides, the inhibitory 
activity of the designed peptides was evaluated by E-rosetting inhibition assay and a 
newly developed heterotypic cell adhesion assay specifically targeting CD2-CD58 
interaction, while CD, NMR and MD were applied to determine 3D structure of the 
peptides in solution.  
Truncation scanning identified the minimum inhibitory sequence (MIS) for the 
12-amino acid parent peptides. The MIS of cER was a hexapeptide (cEL) that showed 
higher activity compared to that of its parent peptide, while the MIS of the other three 
peptides were octapeptides (viz cVR, cQT and cIN) which maintained most of the 
activity of respective parent peptides. For the potent hexapeptide cEL, alanine 
scanning was further carried out to investigate the roles of charged residues. Our 
results suggested that alanine mutagenesis of cEL on charged residues, especially the 
β-turn residue (S4A) significantly reduced the biological activity. And alanine 
mutagenesis of cVL on the Tyr flanking residue (cAY) also resulted in significant loss 
of inhibitory activity.  
The effects of peptides on LFA-1/ICAM-1 adhesion were also evaluated to 
investigate the inhibitory mechanism of the designed peptides. All the peptides 
showed little or no effects on LFA-1 mediated adhesion, suggesting that CD2 derived 
peptides inhibit cell adhesion by blocking CD2-CD58 interaction. Furthermore, all the 
peptides showed no cytotoxicity on Jurkat cells or OVCAR cells at the highest 




concentration (200 mM), suggesting that these peptides could serve as lead 
compounds of immunosuppressive agents. 
Structural studies showed β-turn structure was adopted in the MIS peptides (cQT, 
cIN and cVR). These β-turns were comparable to those found in native CD2 structure 
from which they were derived. On the other hand, alanine mutation of some critical 
residues affected or destroyed the β-turn structure in peptides. Mutation of turn 
residue (S4A) resulted in some percentage of open structure, while mutation of hot 
spot Tyr flanking residue (cAY) possibly affected the stability of the β-turn spanning 
Y2-S3-T4-N5. 
Therefore, our SAR study indicated that the β-turn structure was essential and 
critical for the inhibitory activity of CD2 derived peptides. These β-turns in peptides 
could mimic CD2 ligand binding epitopes thus modulate CD2-CD58 interaction. 
Mutagenesis on critical charged residues involved in hydrogen bonding with CD58 
was functionally deleterious, especially when these residues were inside the β-turn 
(S4A) or flanking the β-turn (cAY), as the mutagenesis might change the peptide 
conformation or their binding sites on CD58.  
In conclusion, our structure-activity relationship study has proved the hypothesis 
that the peptides designed from CD2 critical ligand binding epitopes could modulate 
CD2-CD58 interaction. Furthermore, our study was helpful in the structure-based 
drug design from CD2 protein. For example, the minimum inhibitory sequence (MIS) 
identified in this study could serve as leading compounds or design templates for 
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